{"gene":"UCHL1","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2006,"finding":"UCH-L1 deubiquitinating activity is required for normal synaptic and cognitive function; restoration of UCH-L1 enzymatic activity (via TAT-UCH-L1 fusion protein) rescues beta-amyloid-induced decreases in synaptic function and restores normal levels of PKA-regulatory subunit IIalpha, PKA activity, and CREB phosphorylation in hippocampal slices and APP/PS1 mice.","method":"TAT-fusion protein transduction into hippocampal slices and APP/PS1 mice; enzymatic activity assays; biochemical measurement of PKA-RIIalpha, PKA activity, and CREB phosphorylation; contextual fear conditioning","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro enzyme activity restoration combined with in vivo behavioral rescue and multiple downstream pathway measurements in two independent AD models","pmids":["16923396"],"is_preprint":false},{"year":2002,"finding":"UCH-L1 (PGP9.5) interacts with JAB1 (a Jun activation domain-binding protein involved in p27Kip1 degradation) in vitro and in vivo, and both proteins form a heteromeric complex with p27Kip1 in the nucleus of lung cancer cells; nuclear translocation of UCH-L1 and JAB1 coincides with reduced nuclear p27Kip1 levels, suggesting UCH-L1 contributes to p27Kip1 degradation via JAB1.","method":"Yeast two-hybrid screen; co-immunoprecipitation in vitro and in vivo; colocalization studies; serum restimulation and contact inhibition experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reciprocal Co-IP and colocalization in multiple cell contexts, single lab, no reconstituted degradation assay","pmids":["12082530"],"is_preprint":false},{"year":2013,"finding":"UCH-L1 regulates the balance between mTORC1 and mTORC2 by disrupting the DDB1-CUL4 ubiquitin ligase complex interaction with raptor and counteracting DDB1-CUL4-mediated raptor ubiquitination, leading to mTORC1 dissolution and secondary increase in mTORC2 activity (increased Akt phosphorylation, decreased S6K and 4EBP1 phosphorylation).","method":"Co-immunoprecipitation; ubiquitination assays; mTOR complex assembly analysis; UCHL1-deficient and transgenic mouse models; kinase activity assays for S6K, 4EBP1, and Akt","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ubiquitination assay, genetic mouse models, multiple orthogonal methods in one study demonstrating mechanistic rearrangement of mTOR complexes","pmids":["23297343"],"is_preprint":false},{"year":2008,"finding":"Familial PD-associated I93M mutant UCH-L1 and carbonyl-modified (oxidatively damaged) UCH-L1 share aberrant properties: increased insolubility, elevated interactions with multiple proteins including tubulin, and similar structural changes by circular dichroism; aberrant interaction of mutant or carbonyl-modified UCH-L1 with tubulin modulates tubulin polymerization.","method":"Circular dichroism analysis; solubility fractionation; co-immunoprecipitation/pulldown with tubulin; in vitro tubulin polymerization assay; transgenic mice","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro biochemical assays (CD, polymerization) plus co-IP, single lab, multiple orthogonal methods","pmids":["18250096"],"is_preprint":false},{"year":2018,"finding":"UCH-L1 associates with and promotes assembly of the translation initiation complex eIF4F and stimulates protein synthesis through a mechanism requiring its catalytic (deubiquitinase) activity; this bypasses mTORC1-dependent protein synthesis and is required for MYC-driven lymphomagenesis in Eμ-myc mice.","method":"Proximity-based proteomics (BioID); co-immunoprecipitation; protein synthesis assays; catalytic mutant UCH-L1 transgenic mice; Eμ-myc lymphoma model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — proximity proteomics plus genetic mouse model plus catalytic mutant requirement, multiple orthogonal methods, direct functional readout","pmids":["30257881"],"is_preprint":false},{"year":2006,"finding":"UCH-L1 displays distinct substrate recognition from its homologue UCH-L3; specific ubiquitin side chains critical for forming the Michaelis complex and enabling catalysis by UCH-L1 were identified using a panel of ubiquitin fusions; activation parameters show mechanistic differences in substrate specificity between UCH-L1 and UCH-L3.","method":"In vitro enzymatic assays with ubiquitin fusion panel; kinetic analysis; activation parameter measurements","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro kinetic and mechanistic characterization with multiple substrate variants, single lab but rigorous quantitative biochemistry","pmids":["17144664"],"is_preprint":false},{"year":2022,"finding":"Crystal structure of UCHL1 in complex with inhibitor GK13S reveals the enzyme locked in a hybrid conformation between apo and ubiquitin-bound states; stereoselective inhibition of cellular UCHL1 by GK13S reduces monoubiquitin levels in glioblastoma cells, phenocopying an inactivating mouse mutation of UCHL1.","method":"X-ray crystallography; biochemical characterization of activity-based probes; cellular monoubiquitin measurement; activity-based probe labeling","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with functional validation, stereoselective probe pair, cellular monoubiquitin phenocopy of genetic inactivation, multiple methods","pmids":["36216817"],"is_preprint":false},{"year":2017,"finding":"UCH-L1 directly deubiquitinates TrkB (the BDNF receptor) at lysine K460 in the juxtamembrane domain; UCH-L1-regulated TrkB deubiquitination prevents BDNF-induced TrkB internalization and lysosomal degradation, sustaining surface TrkB levels, TrkB activation, and downstream signaling; blocking UCH-L1–TrkB interaction in vivo impairs hippocampus-dependent memory.","method":"Co-immunoprecipitation; in vitro deubiquitination assay; ubiquitination site mapping (K460); competitive inhibitory peptide; in vivo hippocampal injection and fear conditioning","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct deubiquitination assay, site-specific mutagenesis of K460, competitive peptide inhibition both in vitro and in vivo, behavioral readout","pmids":["28500221"],"is_preprint":false},{"year":2020,"finding":"UCHL1 binds, deubiquitinates, and stabilizes EGFR (epidermal growth factor receptor), thereby activating downstream EGFR mediators and driving pathological cardiac hypertrophy; knockdown of UCHL1 ameliorates hypertrophy while overexpression exacerbates it.","method":"Co-immunoprecipitation; ubiquitination assay; UCHL1 knockdown and overexpression in cardiomyocytes; rAAV9-UCHL1 mouse model; pressure overload model; pharmacological inhibition with LDN-57444","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ubiquitination assay, genetic gain/loss-of-function in cells and two in vivo models, pharmacological validation","pmids":["32494592"],"is_preprint":false},{"year":2020,"finding":"UCHL1 deubiquitinates and stabilizes EGFR, which suppresses ERα transcription, thereby downregulating estrogen receptor alpha expression in breast cancer; UCH-L1 inhibition restores ERα expression and sensitizes ER-negative breast cancer to tamoxifen and fulvestrant in vivo and in vitro.","method":"Immunoprecipitation; ubiquitination assay; luciferase reporter; ChIP assay; qRT-PCR; immunoblotting; in vivo xenograft model","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, ChIP, and in vivo data, single lab, multiple orthogonal methods","pmids":["32042339"],"is_preprint":false},{"year":2013,"finding":"UCH-L1 protects from TNF-induced necroptosis; HtrA2/Omi serine protease induces monoubiquitination of UCH-L1 (indicative of activation) during necroptosis rather than cleaving it; pharmacological or RNAi-mediated inhibition of UCH-L1 protects cells from TNF-induced necroptosis; UCH-L1 is a mediator of caspase-independent cell death in kidney podocytes.","method":"Pharmacological inhibition; RNA interference; cell death assays; monoubiquitination detection; PARP-1 cleavage; caspase activity assays; morphological analysis","journal":"Cell communication and signaling : CCS","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — RNAi plus pharmacological inhibition in multiple cell systems, detection of UCH-L1 monoubiquitination, single lab","pmids":["24090154"],"is_preprint":false},{"year":2019,"finding":"UCHL1 promotes podocyte necroptosis by maintaining deubiquitinated (stabilized) RIPK1 and RIPK3; UCHL1 knockdown reduces half-life and expression of RIPK1 and RIPK3, decreasing MLKL activation and protecting podocytes from high-glucose-induced necroptosis.","method":"UCHL1 siRNA knockdown; protein half-life assay; Western blot for RIPK1, RIPK3, MLKL, caspase-3; cell death assays; scanning electron microscopy; in vivo diabetic nephropathy model","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — knockdown with defined molecular phenotype (protein stability of RIPK1/RIPK3), in vivo model, single lab","pmids":["31247189"],"is_preprint":false},{"year":2019,"finding":"Binding of ischemia-induced reactive lipid species to cysteine C152 of UCHL1 inactivates the enzyme; a C152A knock-in mouse resistant to lipid adduction showed decreased axonal injury, reduced tissue loss, preserved excitatory synaptic drive and axonal conduction velocity, and improved sensorimotor recovery after MCAO, demonstrating that C152 is a key site for post-translational inactivation of UCHL1 by reactive lipids after stroke.","method":"C152A knock-in mouse; middle cerebral artery occlusion (MCAO); histological analysis; electrophysiology; behavioral assessment; polyubiquitinated protein detection","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in mouse with site-specific mutation, multiple in vivo and ex vivo functional readouts, direct identification of the PTM site","pmids":["30760601"],"is_preprint":false},{"year":2020,"finding":"UCHL1 deubiquitinates and stabilizes pyruvate kinase (PKM), promoting glycolysis; loss of UCHL1 destabilizes PKM, reduces pyruvate and ATP levels, activates AMPK, and promotes AMPK-dependent mitophagy via ULK1 and FUNDC1, mitigating PD-related phenotypes caused by PINK1/Parkin loss-of-function. TRIM63 is identified as the E3 ligase for PKM, antagonizing UCHL1.","method":"UCHL1 knockout cells and Drosophila models; PKM stability assay; ATP/pyruvate measurements; AMPK activity assay; mitophagy assays; co-immunoprecipitation; E3 ligase identification","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic models in two organisms plus biochemical substrate validation and E3 ligase identification, multiple orthogonal assays","pmids":["34244144"],"is_preprint":false},{"year":2017,"finding":"UCH-L1 interacts with and promotes K63-linked ubiquitin chain formation on tau, and its inhibition reduces K63-linked ubiquitin chains, decreases HDAC6 deacetylase activity, attenuates HDAC6–tau interaction, and impairs proteasomal impairment-induced tau aggresome formation.","method":"UCH-L1 inhibitor (LDN); UCH-L1 siRNA; immunoprecipitation; ubiquitin chain-linkage analysis; HDAC6 activity assay; tau aggresome immunofluorescence","journal":"Molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — pharmacological inhibitor and siRNA with mechanistic follow-up on K63 chains and HDAC6 activity, single lab","pmids":["28540657"],"is_preprint":false},{"year":2016,"finding":"UCH-L1 inhibition decreases the microtubule-binding ability of tau and increases tau phosphorylation and abnormal ubiquitination; both pharmacological inhibition of UCH-L1 activity (LDN) and siRNA-mediated knockdown produce these effects in neuronal cell lines.","method":"UCH-L1 inhibitor LDN; UCH-L1 siRNA in HEK293/tau441 cells; tau-microtubule binding assay; immunofluorescence; immunoprecipitation; phosphorylation analysis","journal":"Journal of Alzheimer's disease : JAD","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct tau-microtubule binding assay with two independent loss-of-function approaches, single lab","pmids":["26444754"],"is_preprint":false},{"year":2012,"finding":"UCHL1 interacts with NCAM180 (and NCAM140) isoforms of the neural cell adhesion molecule; overexpression of UCHL1 decreases constitutive ubiquitination of NCAM180 and NCAM140 and reduces their lysosomal localization, indicating UCHL1 regulates NCAM ubiquitination and intracellular trafficking/recycling.","method":"Protein macroarray screening; co-immunoprecipitation; colocalization in primary neurons; UCHL1 overexpression and inhibition; ubiquitination assays; lysosomal trafficking assays","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — macroarray plus Co-IP plus functional ubiquitination and trafficking assays, single lab","pmids":["23061666"],"is_preprint":false},{"year":2015,"finding":"UCHL-1 is aberrantly recruited to mitochondria by NH2-terminal tau fragment (NH2htau) in neurons; shRNA-mediated silencing of UCHL-1 (or Parkin) suppresses excessive mitophagy induced by NH2htau, restores synaptic and mitochondrial content, and provides partial protection against NH2htau-induced neuronal death; endogenous NH2htau is associated with UCHL-1 and Parkin in mitochondria from human AD synapses.","method":"shRNA silencing of UCHL-1; mitophagy assays; mitochondrial fractionation; co-immunoprecipitation from human AD synaptic mitochondria; cell viability assays; primary hippocampal neurons","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — shRNA knockdown in neurons with functional readouts plus human AD tissue co-IP validation, single lab","pmids":["25687137"],"is_preprint":false},{"year":2020,"finding":"UCHL1 deubiquitinates CD36 (a scavenger receptor), stabilizing it and promoting oxidized LDL uptake and foam cell formation; UCHL1 inhibition or deletion increases K48-polyubiquitination of CD36 and reduces its protein levels, decreasing lipid accumulation.","method":"UCHL1 siRNA; UCHL1 inhibitor; ubiquitination assay for CD36; Western blot; lipid uptake assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ubiquitination assay plus two independent loss-of-function approaches with defined substrate (CD36), single lab","pmids":["32801299"],"is_preprint":false},{"year":2021,"finding":"UCHL1 interacts with IκBα protein and inhibits its K48-linked ubiquitination and proteasomal degradation; UCHL1 inhibition blocks LPS-induced IκBα degradation, suppresses NF-κB nuclear translocation, reduces ERK1/2 phosphorylation, and decreases pro-inflammatory cytokine production in macrophages.","method":"Co-immunoprecipitation; ubiquitination assay; UCHL1 inhibitor; Western blot for IκBα, phospho-ERK1/2, NF-κB; ELISA for IL-6 and TNF-α; in vivo LPS model","journal":"Cell biology international","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct Co-IP with IκBα, ubiquitination assay, pharmacological inhibition with in vivo validation, single lab","pmids":["34288216"],"is_preprint":false},{"year":2019,"finding":"UCHL1 regulates mTORC1 and mTORC2 balance in skeletal muscle; skeletal muscle-specific knockout of UCHL1 increases mTORC1 activity and decreases mTORC2 activity in slow-twitch (soleus) but not fast-twitch (EDL) muscle, leading to enlarged slow-twitch muscle fibers; UCHL1 knockdown decreases PRAS40 protein turnover, contributing to increased mTORC1 activity.","method":"Skeletal muscle-specific UCHL1 knockout mice; C2C12 siRNA knockdown; mTORC1/2 activity assays (phosphorylation of downstream targets); fiber type staining; PRAS40 protein turnover assay","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific knockout plus cell-based knockdown with consistent mTOR complex phenotype, single lab","pmids":["31356902"],"is_preprint":false},{"year":2020,"finding":"UCHL1 hydrolase activity is required for normal axonal conduction and protection after traumatic brain injury; C90A knock-in mice (devoid of hydrolase activity) show increased axonal injury, greater hippocampal neuron loss, elevated polyubiquitinated proteins and Beclin-1 after controlled cortical impact, suggesting the hydrolase activity maintains UPS function and suppresses autophagy after TBI.","method":"C90A hydrolase-dead knock-in mouse; controlled cortical impact TBI model; histology; immunohistochemistry for APP and SMI-32; polyubiquitin and Beclin-1 Western blot; behavioral beam balance test","journal":"Experimental neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in mouse with site-specific active-site mutation, multiple histological and molecular readouts in vivo, direct attribution of hydrolase activity to axonal protection","pmids":["33159930"],"is_preprint":false},{"year":2024,"finding":"UCHL1 interacts with the NACHT domain of NLRP3 inflammasome; UCH-L1 downregulation decreases pro-IL-1β levels; pharmacological UCH-L1 inhibition interferes with NLRP3 puncta formation and ASC oligomerization, reducing IL-1β cleavage and secretion particularly in microglia.","method":"Proximity labeling (affinity purification); RNAi screening; co-immunoprecipitation; NLRP3 puncta imaging; ASC oligomerization assay; UCHL1 chemical inhibition; IL-1β ELISA","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — proximity labeling plus direct Co-IP of UCHL1–NLRP3, pharmacological and genetic validation, single study","pmids":["38669140"],"is_preprint":false},{"year":2001,"finding":"Uch-L1 and Uch-L3 have both separate and overlapping functions in maintaining axonal integrity: double Uch-L1/Uch-L3 knockout mice display earlier lethality, dysphagia, and more severe axonal degeneration of the gracile tract, nucleus tractus solitarius, and area postrema than either single knockout, demonstrating redundant and distinct roles in neuronal maintenance.","method":"Uch-L1/Uch-L3 double-knockout mouse generation; histological analysis of axonal degeneration; behavioral and survival analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via double-knockout mouse with clear quantitative neurodegeneration phenotypes, establishes functional redundancy and distinct roles","pmids":["11555633"],"is_preprint":false},{"year":2024,"finding":"UCHL1 deubiquitinates and stabilizes Sox17 in endothelial cells; conditional UCHL1 knockout impairs endothelial cell proliferation, migration, tube formation, angiogenesis, and blood-spinal cord barrier recovery after spinal cord injury, while UCHL1 overexpression promotes these processes.","method":"Immunoprecipitation-mass spectrometry; co-immunoprecipitation; conditional UCHL1 knockout mice; Sox17 knockdown/overexpression; in vitro endothelial cell assays; in vivo SCI model","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — IP-MS identification plus Co-IP validation, conditional KO mice with functional rescue, single lab","pmids":["38478109"],"is_preprint":false},{"year":2025,"finding":"UCHL1 stabilizes PFKFB3 (a glycolytic regulator) in astrocytes by cleaving K48-linked ubiquitin chains; UCHL1/PFKFB3 axis increases lactate production, leading to histone H4K8 lactylation and subsequent transcriptional upregulation of Uchl1 and glycolysis genes, forming a positive feedback loop that sustains astrocytic glycolytic reprogramming and prevents neuronal ferroptosis after spinal cord injury.","method":"Genetic Uchl1 deletion; PFKFB3 knockout; K48-linked ubiquitination assay; histone lactylation assay; co-immunoprecipitation; scRNA-seq analysis; in vivo SCI model","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ubiquitination assay plus genetic models plus histone lactylation measurement, single lab, multiple methods","pmids":["40016338"],"is_preprint":false},{"year":2024,"finding":"RANKL stimulates UCHL1 expression in osteoclast precursors; UCHL1 stabilizes CD13 (deubiquitinates it), augmenting soluble CD13 (sCD13) release, which exerts an autocrine inhibitory effect on the MAPK pathway to suppress osteoclast formation; conditional UCHL1 deletion in osteoclast precursors exacerbates OA while overexpression alleviates it.","method":"Conditional UCHL1 knockout mice; AAV9-UCHL1 overexpression; osteoclast differentiation assays; co-immunoprecipitation; ubiquitination assay for CD13; MAPK pathway analysis; human and murine OA specimens","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout plus viral overexpression in vivo, direct ubiquitination of substrate CD13, defined autocrine signaling mechanism, two species validation","pmids":["39389988"],"is_preprint":false},{"year":2023,"finding":"UCHL1 deubiquitinates and stabilizes TAZ at K46 (removing K48-linked polyubiquitin); stabilized TAZ competes with calcineurin A (CNA) for binding to NFATC1, inhibiting NFATC1 dephosphorylation and nuclear transport, thereby suppressing osteoclastogenesis; osteoclast-specific UCHL1 knockout mice develop severe osteoporosis.","method":"Osteoclast-specific conditional UCHL1 knockout mice; co-immunoprecipitation; in vitro ubiquitination/deubiquitination assay; K46 mutagenesis; NFATC1 nuclear transport assay; ovariectomy bone loss model","journal":"International journal of biological sciences","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — site-specific K46 mutagenesis, reconstituted deubiquitination assay, conditional knockout in vivo, mechanistic competition assay for NFATC1","pmids":["37215988"],"is_preprint":false},{"year":2022,"finding":"UCHL1 binds, deubiquitinates, and stabilizes HIF-1α following myocardial infarction; UCHL1 knockout cardiomyocytes (via CRISPR/Cas9 in hiPSCs) show reduced HIF-1α expression and suppressed HIF-1α target genes; recombinant UCHL1 and AAV9-cardiac UCHL1 delivery protect against MI in mice.","method":"BioID proximity labeling + mass spectrometry; CRISPR/Cas9 UCHL1 knockout hiPSC-derived cardiomyocytes; Western blot for HIF-1α; HIF-1α target gene qRT-PCR; recombinant UCHL1 IP injection; AAV9-UCHL1 cardiac delivery; MI mouse model","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — BioID plus genetic KO plus in vivo AAV delivery, direct HIF-1α stabilization demonstrated, single lab","pmids":["35339825"],"is_preprint":false},{"year":2019,"finding":"UCH-L1 regulates lung endothelial barrier function; UCHL1 knockdown or pharmacological inhibition (LDN-57444) decreases VE-cadherin and claudin-5 expression, reduces barrier enhancement by HGF, and increases thrombin-induced permeability; silencing FoxO1 transcription factor restores claudin-5 levels; UCHL1 inhibition in vivo increases ventilator-induced lung injury.","method":"UCHL1 siRNA; LDN-57444 inhibitor; transendothelial electrical resistance; VE-cadherin and claudin-5 Western blot; FoxO1 siRNA rescue; murine VILI model","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — pharmacological and genetic inhibition with mechanistic rescue experiment, in vivo validation, single lab","pmids":["33438509"],"is_preprint":false},{"year":2024,"finding":"UCHL1 deficiency attenuates pulmonary arterial hypertension via reduction of AKT1; UCHL1 deubiquitinates AKT1 (specifically promotes K63-linked and reduces K48-linked ubiquitination), maintaining higher AKT1 levels; Uchl1 knockout rats and conditional Uchl1 knockout mice show reduced right ventricular hypertrophy, pressure, and vascular remodeling.","method":"UCHL1-silenced human pulmonary artery endothelial cells; Uchl1 knockout rats; conditional Uchl1 knockout mice (Tie2Cre); LDN57444 pharmacological inhibition; K63/K48-ubiquitinated Akt detection; right ventricular hemodynamics; vascular histology; three preclinical PAH models","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple independent genetic models (rat KO, conditional mouse KO, siRNA) plus pharmacological inhibition, K63/K48-ubiquitination assay defines mechanism, three PAH models","pmids":["38695173"],"is_preprint":false},{"year":2023,"finding":"UCHL1 binds, deubiquitinates, and stabilizes POM121 (a nuclear pore complex nucleoporin); stabilized POM121 regulates nuclear transport of E2F1 and c-MYC, maintaining neuroendocrine differentiation and promoting cancer progression in neuroendocrine carcinomas.","method":"Co-immunoprecipitation; deubiquitination assay; loss-of-function (siRNA/UCHL1 KO); nuclear fractionation for E2F1 and c-MYC; in vivo tumor growth and metastasis assays; UCHL1 inhibitor LDN-57444","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and deubiquitination assay, nuclear transport assay, in vivo models, single lab","pmids":["38244540"],"is_preprint":false},{"year":2023,"finding":"UCHL1 interacts with, deubiquitylates, and stabilizes ferredoxin reductase (FDXR), an important mitochondrial iron homeostasis protein; HCMV infection-induced loss of UCHL1 causes FDXR ubiquitination and degradation, leading to mitochondrial iron overload, AIM2 inflammasome activation, and vascular endothelial inflammatory injury.","method":"Co-immunoprecipitation; ubiquitination assay for FDXR; UCHL1 knockdown; HCMV infection model; mitochondrial iron measurement; AIM2 inflammasome activation assay; MCMV-infected mice","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP with deubiquitination assay, in vivo mouse model validation, single lab","pmids":["38081437"],"is_preprint":false},{"year":2019,"finding":"UCH-L1 promotes cross-presentation of antigens by dendritic cells by facilitating MHC class I molecule recycling; UCH-L1-deficient DCs have reduced ability to generate MHC I–peptide complexes and to cross-prime CD8 T cells in vivo; antigen uptake and phagosome maturation are unaffected, while intracellular MHC I colocalization with late endosomal/lysosomal compartments is reduced.","method":"UCH-L1-deficient mice; in vivo and in vitro CD8 T cell cross-priming assays; MHC I recycling assay; phagocytosis and phagosome maturation assays; MHC I colocalization imaging","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with in vivo and in vitro functional assays, mechanistic exclusion of upstream steps and identification of MHC I recycling as the step regulated by UCHL1, single lab","pmids":["31492742"],"is_preprint":false},{"year":2014,"finding":"UCH-L1 activity increases podocyte hypertrophy and total protein content in membranous nephropathy; mechanistically, UCH-L1 increases cytoplasmic p27Kip1 by promoting its nuclear export and decreasing its poly-ubiquitination and proteasomal degradation; inhibition of UCH-L1 attenuates podocyte hypertrophy.","method":"UCH-L1 overexpression and knockdown in podocytes; UCH-L1 inhibitor; p27Kip1 nuclear/cytoplasmic fractionation; ubiquitination assay for p27Kip1; protein content measurement; human and rat MGN tissue analysis","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — gain and loss of function with mechanistic ubiquitination and localization assay for defined substrate p27Kip1, single lab","pmids":["24583340"],"is_preprint":false},{"year":2016,"finding":"UCH-L1 absence causes pure motor neuropathy with selective degeneration of motor (not sensory) axons; neuromuscular junctions are impaired in both slow- and fast-twitch muscle groups but spinal motor neuron cell bodies remain intact without signs of ER stress, indicating UCHL1 is specifically required for NMJ and motor axon maintenance rather than motor neuron survival.","method":"Uchl1(nm3419) UCHL1-/- mice; molecular and cellular marker expression analysis; electrophysiological recordings; NMJ morphological analysis; axon and sensory neuron histology","journal":"Annals of clinical and translational neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — defined genetic null mouse with comprehensive cellular and electrophysiological phenotyping distinguishing motor vs sensory axons and cell bodies","pmids":["27231703"],"is_preprint":false},{"year":2021,"finding":"UCHL1 promotes HGSOC (high-grade serous ovarian cancer) growth by maintaining protein homeostasis via the PSMA7-APEH-proteasome axis; UCHL1 silencing reduces PSMA7 and APEH expression and proteasome activity, causes polyubiquitinated protein accumulation, attenuates mTORC1 activity and protein synthesis, and induces terminal UPR.","method":"UCHL1 siRNA in HGSOC cells; in vivo xenograft metastasis model; transcriptional profiling; PSMA7 and APEH knockdown; proteasome activity assay; polyubiquitin accumulation; mTORC1 signaling assay","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — siRNA with in vivo xenograft, mechanistic cascade (PSMA7-APEH-proteasome) defined by sequential knockdown, single lab","pmids":["33753553"],"is_preprint":false},{"year":2013,"finding":"NF-κB transcription factor binds the UCH-L1 promoter at –300 bp and –109 bp sites and upregulates UCH-L1 expression; TNF-α and IL-1β cytokine stimulation of podocytes activates NF-κB and rapidly increases UCH-L1 mRNA and protein, while NF-κB inhibition (PDTC) prevents this upregulation.","method":"Electrophoretic mobility shift assay (EMSA); promoter reporter analysis; NF-κB inhibitor (PDTC); cytokine stimulation of podocytes; Western blot and qRT-PCR; immunohistochemistry of human lupus nephritis biopsies","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA demonstrating direct NF-κB–promoter binding plus pharmacological inhibition, single lab","pmids":["23567262"],"is_preprint":false},{"year":2017,"finding":"UCH-L1 promotes breast cancer cell invasion by interacting preferentially with Akt2 and activating Akt signaling; proximity-dependent BioID identified UCH-L1–Akt interaction, confirmed by pulldown with His-tagged recombinant UCH-L1 from cell lysate; UCH-L1 overexpression increases phosphorylated Akt while knockdown suppresses invasion.","method":"BioID proximity labeling; streptavidin pulldown; His-tagged recombinant UCH-L1 pulldown; phospho-Akt Western blot; invasion assays; UCH-L1 siRNA","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — BioID plus recombinant pulldown confirming Akt2 interaction, functional invasion readout, single lab","pmids":["28636190"],"is_preprint":false},{"year":1996,"finding":"PGP9.5/UCH-L1 was purified to homogeneity from bovine retina by ubiquitin-Sepharose affinity chromatography; the purified protein displays hydrolytic activity on ubiquitin ethyl ester (UbOEt) and reactivity with cysteine and histidine-specific reagents, confirming it is a cysteine/histidine-dependent ubiquitin C-terminal hydrolase with biochemical properties distinguishable from other UCH family members.","method":"Ubiquitin-Sepharose affinity chromatography; enzymatic assay with UbOEt; cysteine/histidine reagent inhibition; Km determination","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct biochemical purification and enzymatic characterization of the native protein, establishes catalytic mechanism","pmids":["8809066"],"is_preprint":false}],"current_model":"UCHL1 is a neuronal-abundant deubiquitinating enzyme (cysteine/histidine-dependent UCH family) that maintains free ubiquitin homeostasis and directly deubiquitinates and stabilizes multiple substrates—including TrkB, EGFR, HIF-1α, PKM, POM121, TAZ, CD13, CD36, AKT1, FDXR, PFKFB3, Sox17, RIPK1, RIPK3, and raptor—to regulate synaptic plasticity, axonal integrity, mTOR complex balance (disrupting mTORC1/promoting mTORC2), translation initiation (eIF4F assembly), cardiac and pulmonary hypertrophy, immune signaling (NF-κB via IκBα; NLRP3 inflammasome; MHC I recycling in dendritic cells), glycolysis, osteoclastogenesis, and necroptosis; its catalytic cysteine C152 is a critical site of inactivation by reactive lipids generated during ischemia, and loss of its hydrolase activity impairs UPP function and worsens axonal injury after brain trauma."},"narrative":{"mechanistic_narrative":"UCHL1 is a neuronal-abundant, cysteine/histidine-dependent ubiquitin C-terminal hydrolase whose catalytic activity maintains free ubiquitin homeostasis and supports neuronal and synaptic integrity [PMID:8809066, PMID:36216817, PMID:11555633]. Biochemically it is a deubiquitinating enzyme distinguishable from its homologue UCH-L3 by distinct substrate recognition, and structural work captures it in a hybrid conformation between apo and ubiquitin-bound states whose inhibition lowers cellular monoubiquitin, phenocopying genetic inactivation [PMID:17144664, PMID:36216817]. Genetic loss of UCHL1 alone or together with UCH-L3 produces progressive axonal degeneration, and selective motor axon and neuromuscular-junction failure, establishing its role in neuronal maintenance rather than neuron survival [PMID:11555633, PMID:27231703]. Across many cell types UCHL1 acts as a substrate-stabilizing DUB: it deubiquitinates and stabilizes TrkB to sustain BDNF signaling and memory, EGFR to drive cardiac hypertrophy and ER-negative breast cancer, HIF-1α after myocardial infarction, AKT1 in pulmonary hypertension, and metabolic and trafficking substrates including PKM, PFKFB3, CD36, CD13, POM121, Sox17, and FDXR [PMID:28500221, PMID:32494592, PMID:32042339, PMID:35339825, PMID:38695173, PMID:34244144, PMID:40016338, PMID:32801299, PMID:39389988, PMID:38244540, PMID:38478109, PMID:38081437]. Through these substrates UCHL1 regulates glycolytic reprogramming, mitophagy, mTOR complex balance, and endothelial barrier and angiogenic function [PMID:34244144, PMID:23297343, PMID:38478109, PMID:33438509]. It also restrains necroptosis by stabilizing RIPK1/RIPK3, modulates NF-κB and NLRP3 inflammasome signaling in myeloid cells, and promotes MHC class I recycling for dendritic-cell cross-presentation [PMID:31247189, PMID:34288216, PMID:38669140, PMID:31492742]. Its catalytic activity is itself a regulated node: the active-site cysteine C152 is inactivated by ischemia-generated reactive lipids, and hydrolase-dead knock-in mice show worsened axonal injury after trauma, linking loss of UCHL1 catalysis to impaired ubiquitin-proteasome function [PMID:30760601, PMID:33159930].","teleology":[{"year":1996,"claim":"Established the biochemical identity of UCHL1 as a catalytic enzyme, defining the mechanistic basis for all subsequent functional work.","evidence":"Affinity purification of native PGP9.5/UCH-L1 from bovine retina with enzymatic and active-site reagent characterization","pmids":["8809066"],"confidence":"High","gaps":["Cellular substrates not addressed","Physiological role undefined"]},{"year":2001,"claim":"Answered whether UCHL1 is required for neuronal maintenance by showing genetic loss causes axonal degeneration with partial redundancy to UCH-L3.","evidence":"Uch-L1/Uch-L3 double-knockout mice with histological axonal phenotyping","pmids":["11555633"],"confidence":"High","gaps":["Molecular substrates driving degeneration not identified","Mechanism of redundancy unresolved"]},{"year":2002,"claim":"First interactor work linking UCHL1 to cell-cycle control via JAB1 and p27Kip1 in a nuclear complex.","evidence":"Yeast two-hybrid, reciprocal Co-IP and colocalization in lung cancer cells","pmids":["12082530"],"confidence":"Medium","gaps":["No reconstituted degradation assay","Direct DUB activity on p27Kip1 not shown"]},{"year":2006,"claim":"Demonstrated that UCHL1 enzymatic activity is functionally required for synaptic plasticity and memory, connecting its DUB activity to PKA/CREB signaling.","evidence":"TAT-UCH-L1 transduction and rescue in hippocampal slices and APP/PS1 mice with behavioral readout","pmids":["16923396"],"confidence":"High","gaps":["Direct synaptic substrate not identified","Mechanism linking DUB activity to PKA-RIIalpha unclear"]},{"year":2006,"claim":"Defined the mechanistic basis of UCHL1 substrate specificity distinct from UCH-L3 at the level of Michaelis-complex formation.","evidence":"In vitro kinetics with a ubiquitin fusion panel","pmids":["17144664"],"confidence":"High","gaps":["Physiological substrates not tested","No structural correlate at the time"]},{"year":2008,"claim":"Connected PD-associated and oxidatively damaged UCHL1 to a gain of aberrant tubulin interaction, providing a toxicity mechanism.","evidence":"Circular dichroism, solubility fractionation, tubulin pulldown and polymerization assays in transgenic mice","pmids":["18250096"],"confidence":"Medium","gaps":["Single lab","Causal link to neurodegeneration in vivo incomplete"]},{"year":2013,"claim":"Revealed that UCHL1 reorganizes mTOR complex balance by counteracting DDB1-CUL4-mediated raptor ubiquitination, shifting activity from mTORC1 to mTORC2.","evidence":"Co-IP, ubiquitination assays and genetic mouse models with kinase activity readouts","pmids":["23297343"],"confidence":"High","gaps":["Whether raptor is a direct DUB substrate vs ligase disruption not fully separated"]},{"year":2013,"claim":"Established UCHL1 as a pro-necroptotic factor activated by monoubiquitination during TNF-induced caspase-independent death.","evidence":"RNAi and pharmacological inhibition with monoubiquitination detection in podocytes","pmids":["24090154"],"confidence":"Medium","gaps":["Direct necroptotic substrate not identified in this study","Single lab"]},{"year":2013,"claim":"Defined transcriptional control of UCHL1 by NF-κB, embedding it in inflammatory signaling loops.","evidence":"EMSA, promoter reporter and NF-κB inhibition in cytokine-stimulated podocytes","pmids":["23567262"],"confidence":"Medium","gaps":["Other transcriptional regulators not excluded"]},{"year":2014,"claim":"Showed UCHL1 stabilizes cytoplasmic p27Kip1 by promoting nuclear export and reducing its ubiquitination, driving podocyte hypertrophy.","evidence":"Gain/loss of function with fractionation and ubiquitination assays in podocytes and disease tissue","pmids":["24583340"],"confidence":"Medium","gaps":["Direct vs indirect deubiquitination of p27Kip1 not resolved"]},{"year":2017,"claim":"Identified TrkB as a direct UCHL1 substrate, explaining how UCHL1 sustains BDNF signaling and memory by preventing receptor degradation.","evidence":"In vitro deubiquitination, K460 site mapping and competitive peptide with in vivo behavioral readout","pmids":["28500221"],"confidence":"High","gaps":["Recruitment of UCHL1 to TrkB unclear"]},{"year":2016,"claim":"Linked UCHL1 activity to tau microtubule binding and phosphorylation, implicating it in cytoskeletal/aggregation pathways.","evidence":"Inhibitor and siRNA in neuronal cells with tau-microtubule binding assays","pmids":["26444754","28540657"],"confidence":"Medium","gaps":["Whether tau is a direct substrate not shown","K63-chain mechanism via HDAC6 single lab"]},{"year":2015,"claim":"Connected UCHL1 to excessive mitophagy when aberrantly recruited to mitochondria by an N-terminal tau fragment.","evidence":"shRNA silencing with mitophagy and viability assays plus human AD synaptic mitochondria Co-IP","pmids":["25687137"],"confidence":"Medium","gaps":["Mechanism of mitochondrial recruitment unresolved"]},{"year":2018,"claim":"Showed UCHL1 promotes eIF4F assembly and protein synthesis independent of mTORC1, a catalytic-activity-dependent route required for MYC-driven lymphoma.","evidence":"BioID, Co-IP, protein synthesis assays and catalytic-mutant mice in Eu-myc model","pmids":["30257881"],"confidence":"High","gaps":["Direct DUB substrate within eIF4F not pinpointed"]},{"year":2019,"claim":"Extended mTOR-balance regulation to skeletal muscle, with PRAS40 turnover as a contributing node.","evidence":"Muscle-specific knockout and C2C12 knockdown with mTORC1/2 readouts","pmids":["31356902"],"confidence":"Medium","gaps":["Fiber-type selectivity mechanism unexplained"]},{"year":2019,"claim":"Defined a role in dendritic-cell cross-presentation by promoting MHC class I recycling rather than uptake or phagosome maturation.","evidence":"UCHL1-deficient mice with cross-priming, recycling and colocalization assays","pmids":["31492742"],"confidence":"Medium","gaps":["Molecular substrate controlling recycling not identified"]},{"year":2019,"claim":"Established UCHL1 maintenance of endothelial barrier integrity via junctional protein expression and a FoxO1 axis.","evidence":"siRNA and LDN-57444 with TEER, junction protein blots, FoxO1 rescue and VILI model","pmids":["33438509"],"confidence":"Medium","gaps":["Direct substrate linking UCHL1 to claudin-5/FoxO1 unknown"]},{"year":2019,"claim":"Identified RIPK1/RIPK3 as stability-dependent effectors through which UCHL1 promotes podocyte necroptosis.","evidence":"siRNA with protein half-life and MLKL activation assays plus diabetic nephropathy model","pmids":["31247189"],"confidence":"Medium","gaps":["Direct deubiquitination of RIPK1/RIPK3 not formally demonstrated"]},{"year":2019,"claim":"Determined that ischemia-generated reactive lipids inactivate UCHL1 at C152, identifying a stroke-relevant post-translational off-switch.","evidence":"C152A knock-in mice with MCAO, electrophysiology and behavior","pmids":["30760601"],"confidence":"High","gaps":["Identity of all relevant lipid adducts not catalogued"]},{"year":2020,"claim":"Identified EGFR as a UCHL1 substrate driving pathological cardiac hypertrophy and, separately, ERα suppression in breast cancer.","evidence":"Reciprocal Co-IP, ubiquitination assays, in vivo cardiac and xenograft models, pharmacological inhibition","pmids":["32494592","32042339"],"confidence":"High","gaps":["Selectivity of UCHL1 among receptor pools unclear"]},{"year":2020,"claim":"Showed UCHL1 stabilizes CD36 to promote oxLDL uptake and foam-cell formation.","evidence":"siRNA, inhibitor and CD36 ubiquitination assays with lipid uptake readout","pmids":["32801299"],"confidence":"Medium","gaps":["Single lab","In vivo atherosclerosis confirmation limited"]},{"year":2020,"claim":"Demonstrated hydrolase activity per se is required for axonal protection after TBI via maintenance of proteasome function.","evidence":"C90A hydrolase-dead knock-in mice in controlled cortical impact model","pmids":["33159930"],"confidence":"High","gaps":["Specific accumulated substrates after TBI not defined"]},{"year":2021,"claim":"Connected UCHL1 to glycolysis/mitophagy via PKM stabilization, with TRIM63 as the antagonist E3 ligase, mitigating PD-related phenotypes.","evidence":"Knockout cells and Drosophila, PKM stability assays, AMPK/mitophagy readouts and E3 identification","pmids":["34244144"],"confidence":"High","gaps":["Generality across neuronal subtypes untested"]},{"year":2021,"claim":"Defined an anti-inflammatory role through stabilization of IκBα and restraint of NF-κB in macrophages.","evidence":"Co-IP, ubiquitination assay, inhibitor and in vivo LPS model","pmids":["34288216"],"confidence":"Medium","gaps":["Apparent context-dependence vs pro-inflammatory roles unreconciled"]},{"year":2021,"claim":"Showed UCHL1 sustains proteostasis in ovarian cancer through a PSMA7-APEH-proteasome axis supporting mTORC1 and protein synthesis.","evidence":"siRNA, sequential knockdown, proteasome activity and UPR assays with xenograft","pmids":["33753553"],"confidence":"Medium","gaps":["Direct DUB substrate within the axis not identified"]},{"year":2022,"claim":"Provided the crystal structure of UCHL1 with a stereoselective inhibitor, defining a hybrid conformational state and validating monoubiquitin readout of activity.","evidence":"X-ray crystallography, activity-based probes and cellular monoubiquitin measurement","pmids":["36216817"],"confidence":"High","gaps":["Substrate-bound full catalytic cycle structure not captured"]},{"year":2022,"claim":"Identified HIF-1α stabilization by UCHL1 as cardioprotective after myocardial infarction.","evidence":"BioID-MS, CRISPR knockout hiPSC cardiomyocytes and AAV9 delivery in MI model","pmids":["35339825"],"confidence":"Medium","gaps":["Single lab","Direct vs indirect HIF-1α regulation not fully separated"]},{"year":2023,"claim":"Defined dual osteoclast-regulatory mechanisms: TAZ stabilization at K46 to inhibit NFATC1, suppressing osteoclastogenesis.","evidence":"Osteoclast-specific knockout, K46 mutagenesis, reconstituted deubiquitination and NFATC1 transport assays","pmids":["37215988"],"confidence":"High","gaps":["Interplay with other osteoclast substrates unresolved"]},{"year":2023,"claim":"Identified POM121 as a UCHL1 substrate controlling E2F1/c-MYC nuclear transport in neuroendocrine cancers.","evidence":"Co-IP, deubiquitination and nuclear fractionation assays with in vivo models","pmids":["38244540"],"confidence":"Medium","gaps":["Single lab","Selectivity for POM121 among nucleoporins unclear"]},{"year":2023,"claim":"Linked UCHL1 to mitochondrial iron homeostasis and inflammasome control via FDXR stabilization during HCMV infection.","evidence":"Co-IP, ubiquitination assay, knockdown and MCMV-infected mice","pmids":["38081437"],"confidence":"Medium","gaps":["Single lab","How infection lowers UCHL1 not detailed"]},{"year":2024,"claim":"Established UCHL1 as a driver of pulmonary arterial hypertension through AKT1 stabilization via ubiquitin chain editing.","evidence":"Knockout rats, conditional mouse KO, siRNA, inhibitor and K63/K48 ubiquitination assays across three PAH models","pmids":["38695173"],"confidence":"High","gaps":["Mechanism of chain-type switching unresolved"]},{"year":2024,"claim":"Defined UCHL1 interaction with the NLRP3 NACHT domain and its requirement for inflammasome assembly in microglia.","evidence":"Proximity labeling, Co-IP, puncta/ASC oligomerization imaging and chemical inhibition","pmids":["38669140"],"confidence":"Medium","gaps":["Whether NLRP3 is a catalytic substrate not established"]},{"year":2024,"claim":"Showed UCHL1 stabilizes CD13 in osteoclast precursors to generate an autocrine MAPK-inhibitory signal that suppresses osteoclastogenesis in osteoarthritis.","evidence":"Conditional KO and AAV9 overexpression, CD13 ubiquitination assay and MAPK analysis in two species","pmids":["39389988"],"confidence":"High","gaps":["Relationship to TAZ/NFATC1 osteoclast pathway not integrated"]},{"year":2024,"claim":"Demonstrated UCHL1 stabilization of Sox17 supports endothelial angiogenesis and barrier recovery after spinal cord injury.","evidence":"IP-MS, Co-IP, conditional KO mice and endothelial functional assays","pmids":["38478109"],"confidence":"Medium","gaps":["Single lab","Ubiquitination site on Sox17 not mapped"]},{"year":2025,"claim":"Revealed a UCHL1/PFKFB3 glycolytic feedback loop sustained by histone lactylation that protects neurons from ferroptosis after spinal cord injury.","evidence":"Genetic deletion, K48 ubiquitination and histone lactylation assays with scRNA-seq and SCI model","pmids":["40016338"],"confidence":"Medium","gaps":["Single lab","Generality of lactylation feedback beyond astrocytes untested"]},{"year":null,"claim":"How UCHL1 achieves substrate selectivity across its many reported targets and is directed to opposing pro- versus anti-inflammatory and pro- versus anti-survival outcomes in different cell types remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model for substrate recruitment","Context-dependent functional switching mechanism unknown","Most substrate interactions documented in single labs"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[39,5,6,7,13,27,30]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[39,21]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[34,36]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,31,34]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[17,32]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[39,6,2,4,36]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,8,30,38,2]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[19,22,33]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,11]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[13,25,18]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[23,35,7]}],"complexes":["eIF4F","mTORC1","mTORC2","NLRP3 inflammasome"],"partners":["TRKB","EGFR","AKT1","HIF1A","PKM","NLRP3","RIPK1","RIPK3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P09936","full_name":"Ubiquitin carboxyl-terminal hydrolase isozyme L1","aliases":["Neuron cytoplasmic protein 9.5","PGP 9.5","PGP9.5","Ubiquitin thioesterase L1"],"length_aa":223,"mass_kda":24.8,"function":"Deubiquitinase that plays a role in the regulation of several processes such as maintenance of synaptic function, cardiac function, inflammatory response or osteoclastogenesis (PubMed:22212137, PubMed:23359680). Abrogates the ubiquitination of multiple proteins including WWTR1/TAZ, EGFR, HIF1A and beta-site amyloid precursor protein cleaving enzyme 1/BACE1 (PubMed:22212137, PubMed:25615526). In addition, recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin to maintain a stable pool of monoubiquitin that is a key requirement for the ubiquitin-proteasome and the autophagy-lysosome pathways (PubMed:12408865, PubMed:8639624, PubMed:9774100). Regulates amyloid precursor protein/APP processing by promoting BACE1 degradation resulting in decreased amyloid beta production (PubMed:22212137). Plays a role in the immune response by regulating the ability of MHC I molecules to reach cross-presentation compartments competent for generating Ag-MHC I complexes (By similarity). Mediates the 'Lys-48'-linked deubiquitination of the transcriptional coactivator WWTR1/TAZ leading to its stabilization and inhibition of osteoclastogenesis (By similarity). Deubiquitinates and stabilizes epidermal growth factor receptor EGFR to prevent its degradation and to activate its downstream mediators (By similarity). Modulates oxidative activity in skeletal muscle by regulating key mitochondrial oxidative proteins (By similarity). Enhances the activity of hypoxia-inducible factor 1-alpha/HIF1A by abrogateing its VHL E3 ligase-mediated ubiquitination and consequently inhibiting its degradation (PubMed:25615526)","subcellular_location":"Cytoplasm; Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/P09936/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/UCHL1","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"SAR1B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/UCHL1","total_profiled":1310},"omim":[{"mim_id":"620221","title":"SPASTIC PARAPLEGIA 79A, AUTOSOMAL DOMINANT, WITH ATAXIA; SPG79A","url":"https://www.omim.org/entry/620221"},{"mim_id":"615491","title":"SPASTIC PARAPLEGIA 79B, AUTOSOMAL RECESSIVE; SPG79B","url":"https://www.omim.org/entry/615491"},{"mim_id":"614991","title":"UBIQUITIN CARBOXYL-TERMINAL ESTERASE L1, ANTISENSE; UCH1LAS","url":"https://www.omim.org/entry/614991"},{"mim_id":"613643","title":"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK5","url":"https://www.omim.org/entry/613643"},{"mim_id":"603090","title":"UBIQUITIN CARBOXYL-TERMINAL ESTERASE L3; UCHL3","url":"https://www.omim.org/entry/603090"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":1037.7},{"tissue":"pituitary gland","ntpm":337.4}],"url":"https://www.proteinatlas.org/search/UCHL1"},"hgnc":{"alias_symbol":["PGP9.5","Uch-L1","UCHL-1"],"prev_symbol":["PARK5"]},"alphafold":{"accession":"P09936","domains":[{"cath_id":"3.40.532.10","chopping":"9-220","consensus_level":"medium","plddt":93.8413,"start":9,"end":220}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09936","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09936-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09936-F1-predicted_aligned_error_v6.png","plddt_mean":93.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=UCHL1","jax_strain_url":"https://www.jax.org/strain/search?query=UCHL1"},"sequence":{"accession":"P09936","fasta_url":"https://rest.uniprot.org/uniprotkb/P09936.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09936/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09936"}},"corpus_meta":[{"pmid":"30054151","id":"PMC_30054151","title":"Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study.","date":"2018","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30054151","citation_count":462,"is_preprint":false},{"pmid":"27018834","id":"PMC_27018834","title":"Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury.","date":"2016","source":"JAMA neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27018834","citation_count":397,"is_preprint":false},{"pmid":"16923396","id":"PMC_16923396","title":"Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16923396","citation_count":369,"is_preprint":false},{"pmid":"17586089","id":"PMC_17586089","title":"The functions of UCH-L1 and its relation to neurodegenerative diseases.","date":"2007","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/17586089","citation_count":241,"is_preprint":false},{"pmid":"27515257","id":"PMC_27515257","title":"Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction.","date":"2016","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/27515257","citation_count":232,"is_preprint":false},{"pmid":"19879917","id":"PMC_19879917","title":"UCHL1 (PGP 9.5): neuronal biomarker and ubiquitin system protein.","date":"2009","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19879917","citation_count":214,"is_preprint":false},{"pmid":"15049988","id":"PMC_15049988","title":"Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment.","date":"2004","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/15049988","citation_count":153,"is_preprint":false},{"pmid":"28334432","id":"PMC_28334432","title":"UCH-L1-containing exosomes mediate chemotherapeutic resistance transfer in breast cancer.","date":"2017","source":"Journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28334432","citation_count":110,"is_preprint":false},{"pmid":"25687137","id":"PMC_25687137","title":"NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25687137","citation_count":107,"is_preprint":false},{"pmid":"12082530","id":"PMC_12082530","title":"Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1).","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12082530","citation_count":93,"is_preprint":false},{"pmid":"27074724","id":"PMC_27074724","title":"Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27074724","citation_count":92,"is_preprint":false},{"pmid":"32494592","id":"PMC_32494592","title":"The deubiquitinase UCHL1 regulates cardiac hypertrophy by stabilizing epidermal growth factor receptor.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/32494592","citation_count":92,"is_preprint":false},{"pmid":"16642472","id":"PMC_16642472","title":"Silencing of the UCHL1 gene in human colorectal and ovarian cancers.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16642472","citation_count":90,"is_preprint":false},{"pmid":"34709508","id":"PMC_34709508","title":"S100B, GFAP, UCH-L1 and NSE as predictors of abnormalities on CT imaging following mild traumatic brain injury: a systematic review and meta-analysis of diagnostic test accuracy.","date":"2021","source":"Neurosurgical review","url":"https://pubmed.ncbi.nlm.nih.gov/34709508","citation_count":89,"is_preprint":false},{"pmid":"16450370","id":"PMC_16450370","title":"UCHL-1 is not a Parkinson's disease susceptibility gene.","date":"2006","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16450370","citation_count":83,"is_preprint":false},{"pmid":"11555633","id":"PMC_11555633","title":"Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11555633","citation_count":81,"is_preprint":false},{"pmid":"36681249","id":"PMC_36681249","title":"Role of UCHL1 in the pathogenesis of neurodegenerative diseases and brain injury.","date":"2023","source":"Ageing research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/36681249","citation_count":79,"is_preprint":false},{"pmid":"18250096","id":"PMC_18250096","title":"Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18250096","citation_count":78,"is_preprint":false},{"pmid":"27702698","id":"PMC_27702698","title":"Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia.","date":"2016","source":"Ageing research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27702698","citation_count":78,"is_preprint":false},{"pmid":"28434268","id":"PMC_28434268","title":"Ubiquitin C-terminal hydrolase-L1 (UCH-L1) as a therapeutic and diagnostic target in neurodegeneration, neurotrauma and neuro-injuries.","date":"2017","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/28434268","citation_count":72,"is_preprint":false},{"pmid":"30760601","id":"PMC_30760601","title":"Role of UCHL1 in axonal injury and functional recovery after cerebral ischemia.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30760601","citation_count":70,"is_preprint":false},{"pmid":"23297343","id":"PMC_23297343","title":"Ubiquitin hydrolase UCH-L1 destabilizes mTOR complex 1 by antagonizing DDB1-CUL4-mediated ubiquitination of raptor.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23297343","citation_count":68,"is_preprint":false},{"pmid":"34497382","id":"PMC_34497382","title":"UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology.","date":"2021","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34497382","citation_count":66,"is_preprint":false},{"pmid":"16585221","id":"PMC_16585221","title":"PGP9.5 methylation in diffuse-type gastric cancer.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16585221","citation_count":65,"is_preprint":false},{"pmid":"31247189","id":"PMC_31247189","title":"High glucose-induced apoptosis and necroptosis in podocytes is regulated by UCHL1 via RIPK1/RIPK3 pathway.","date":"2019","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/31247189","citation_count":65,"is_preprint":false},{"pmid":"24090154","id":"PMC_24090154","title":"The proteases HtrA2/Omi and UCH-L1 regulate TNF-induced necroptosis.","date":"2013","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/24090154","citation_count":56,"is_preprint":false},{"pmid":"19141079","id":"PMC_19141079","title":"Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.","date":"2009","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19141079","citation_count":55,"is_preprint":false},{"pmid":"18512240","id":"PMC_18512240","title":"The role of PGP9.5 as a tumor suppressor gene in human cancer.","date":"2008","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18512240","citation_count":54,"is_preprint":false},{"pmid":"32445783","id":"PMC_32445783","title":"Serum GFAP and UCH-L1 for the prediction of neurological outcome in comatose cardiac arrest patients.","date":"2020","source":"Resuscitation","url":"https://pubmed.ncbi.nlm.nih.gov/32445783","citation_count":52,"is_preprint":false},{"pmid":"34244144","id":"PMC_34244144","title":"Loss of UCHL1 rescues the defects related to Parkinson's disease by suppressing glycolysis.","date":"2021","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/34244144","citation_count":51,"is_preprint":false},{"pmid":"15491288","id":"PMC_15491288","title":"Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells.","date":"2004","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/15491288","citation_count":48,"is_preprint":false},{"pmid":"14571718","id":"PMC_14571718","title":"PGP9.5 overexpression in esophageal squamous cell carcinoma.","date":"2003","source":"Hepato-gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/14571718","citation_count":48,"is_preprint":false},{"pmid":"28636190","id":"PMC_28636190","title":"UCH-L1 promotes invasion of breast cancer cells through activating Akt signaling pathway.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28636190","citation_count":46,"is_preprint":false},{"pmid":"32483437","id":"PMC_32483437","title":"The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32483437","citation_count":46,"is_preprint":false},{"pmid":"1331034","id":"PMC_1331034","title":"cDNA cloning and tissue distribution of a rat ubiquitin carboxyl-terminal hydrolase PGP9.5.","date":"1992","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1331034","citation_count":44,"is_preprint":false},{"pmid":"32042339","id":"PMC_32042339","title":"UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32042339","citation_count":43,"is_preprint":false},{"pmid":"19214988","id":"PMC_19214988","title":"UCH-L1 expression of podocytes in diseased glomeruli and in vitro.","date":"2009","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19214988","citation_count":42,"is_preprint":false},{"pmid":"32801299","id":"PMC_32801299","title":"Deubiquitination of CD36 by UCHL1 promotes foam cell formation.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32801299","citation_count":42,"is_preprint":false},{"pmid":"36112902","id":"PMC_36112902","title":"UCHL1 Impairs Periodontal Ligament Stem Cell Osteogenesis in Periodontitis.","date":"2022","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/36112902","citation_count":40,"is_preprint":false},{"pmid":"27416022","id":"PMC_27416022","title":"Are UCH-L1 and GFAP promising biomarkers for children with mild traumatic brain injury?","date":"2016","source":"Brain injury","url":"https://pubmed.ncbi.nlm.nih.gov/27416022","citation_count":40,"is_preprint":false},{"pmid":"38275158","id":"PMC_38275158","title":"The game changer: UCH-L1 and GFAP-based blood test as the first marketed in vitro diagnostic test for mild traumatic brain injury.","date":"2024","source":"Expert review of molecular diagnostics","url":"https://pubmed.ncbi.nlm.nih.gov/38275158","citation_count":39,"is_preprint":false},{"pmid":"19035297","id":"PMC_19035297","title":"PGP9.5 methylation as a marker for metastatic colorectal cancer.","date":"2008","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19035297","citation_count":39,"is_preprint":false},{"pmid":"39230905","id":"PMC_39230905","title":"Diagnostic Performance of GFAP, UCH-L1, and MAP-2 Within 30 and 60 Minutes of Traumatic Brain Injury.","date":"2024","source":"JAMA network open","url":"https://pubmed.ncbi.nlm.nih.gov/39230905","citation_count":38,"is_preprint":false},{"pmid":"35339825","id":"PMC_35339825","title":"UCHL1 protects against ischemic heart injury via activating HIF-1α signal pathway.","date":"2022","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/35339825","citation_count":36,"is_preprint":false},{"pmid":"30257881","id":"PMC_30257881","title":"UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/30257881","citation_count":36,"is_preprint":false},{"pmid":"27231703","id":"PMC_27231703","title":"Absence of UCHL 1 function leads to selective motor neuropathy.","date":"2016","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27231703","citation_count":35,"is_preprint":false},{"pmid":"27571062","id":"PMC_27571062","title":"Wnt/β-Catenin Signaling Mediated-UCH-L1 Expression in Podocytes of Diabetic Nephropathy.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27571062","citation_count":35,"is_preprint":false},{"pmid":"24086249","id":"PMC_24086249","title":"Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24086249","citation_count":35,"is_preprint":false},{"pmid":"15221445","id":"PMC_15221445","title":"Genetic causes of Parkinson's disease: UCHL-1.","date":"2004","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/15221445","citation_count":34,"is_preprint":false},{"pmid":"29087740","id":"PMC_29087740","title":"The diagnostic values of UCH-L1 in traumatic brain injury: A meta-analysis.","date":"2017","source":"Brain injury","url":"https://pubmed.ncbi.nlm.nih.gov/29087740","citation_count":32,"is_preprint":false},{"pmid":"36216817","id":"PMC_36216817","title":"Structural basis for specific inhibition of the deubiquitinase UCHL1.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36216817","citation_count":32,"is_preprint":false},{"pmid":"11437990","id":"PMC_11437990","title":"Ubiquitin C-terminal hydrolase-L1 (PGP9.5) expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines, neurotrophic factors or heat stress.","date":"2001","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/11437990","citation_count":32,"is_preprint":false},{"pmid":"38244540","id":"PMC_38244540","title":"UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38244540","citation_count":31,"is_preprint":false},{"pmid":"17144664","id":"PMC_17144664","title":"Substrate recognition and catalysis by UCH-L1.","date":"2006","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17144664","citation_count":31,"is_preprint":false},{"pmid":"1824848","id":"PMC_1824848","title":"Reduction in the number of UCHL-1+ cells and IL-2 production in the peripheral blood of patients with visceral leishmaniasis.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1824848","citation_count":31,"is_preprint":false},{"pmid":"9192981","id":"PMC_9192981","title":"Low specificity of PGP9.5 expression for detection of micrometastatic neuroblastoma.","date":"1997","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9192981","citation_count":30,"is_preprint":false},{"pmid":"40016338","id":"PMC_40016338","title":"Metabolic reprogramming in astrocytes prevents neuronal death through a UCHL1/PFKFB3/H4K8la positive feedback loop.","date":"2025","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/40016338","citation_count":28,"is_preprint":false},{"pmid":"26899237","id":"PMC_26899237","title":"Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.","date":"2017","source":"Current protein & peptide science","url":"https://pubmed.ncbi.nlm.nih.gov/26899237","citation_count":27,"is_preprint":false},{"pmid":"26444754","id":"PMC_26444754","title":"UCH-L1 Inhibition Decreases the Microtubule-Binding Function of Tau Protein.","date":"2016","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/26444754","citation_count":26,"is_preprint":false},{"pmid":"33753553","id":"PMC_33753553","title":"Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma.","date":"2021","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/33753553","citation_count":26,"is_preprint":false},{"pmid":"38669140","id":"PMC_38669140","title":"Proximity proteomics reveals UCH-L1 as an essential regulator of NLRP3-mediated IL-1β production in human macrophages and microglia.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38669140","citation_count":25,"is_preprint":false},{"pmid":"23567262","id":"PMC_23567262","title":"The regulation of the UCH-L1 gene by transcription factor NF-κB in podocytes.","date":"2013","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/23567262","citation_count":25,"is_preprint":false},{"pmid":"28500221","id":"PMC_28500221","title":"Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) Promotes Hippocampus-Dependent Memory via Its Deubiquitinating Effect on TrkB.","date":"2017","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28500221","citation_count":25,"is_preprint":false},{"pmid":"34686609","id":"PMC_34686609","title":"The Epstein-Barr virus noncoding RNA EBER2 transactivates the UCHL1 deubiquitinase to accelerate cell growth.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34686609","citation_count":25,"is_preprint":false},{"pmid":"12008752","id":"PMC_12008752","title":"Expression of PGP9.5 in ductal cells of the rat pancreas during development and regeneration: can it be a marker for pancreatic progenitor cells?","date":"2002","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/12008752","citation_count":24,"is_preprint":false},{"pmid":"39389988","id":"PMC_39389988","title":"A RANKL-UCHL1-sCD13 negative feedback loop limits osteoclastogenesis in subchondral bone to prevent osteoarthritis progression.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39389988","citation_count":23,"is_preprint":false},{"pmid":"24959670","id":"PMC_24959670","title":"N-terminal truncated UCH-L1 prevents Parkinson's disease associated damage.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24959670","citation_count":23,"is_preprint":false},{"pmid":"31279265","id":"PMC_31279265","title":"UCH-L1 is a Poor Serum Biomarker of Murine Traumatic Brain Injury After Polytrauma.","date":"2019","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/31279265","citation_count":22,"is_preprint":false},{"pmid":"7679873","id":"PMC_7679873","title":"Differentiation of reactive from neoplastic small-cell lymphoid aggregates in paraffin-embedded marrow particle preparations using L-26 (CD20) and UCHL-1 (CD45RO) monoclonal antibodies.","date":"1993","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7679873","citation_count":21,"is_preprint":false},{"pmid":"31356902","id":"PMC_31356902","title":"UCHL1 regulates muscle fibers and mTORC1 activity in skeletal muscle.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31356902","citation_count":21,"is_preprint":false},{"pmid":"35153498","id":"PMC_35153498","title":"UCHL1 Promoted Polarization of M1 Macrophages by Regulating the PI3K/AKT Signaling Pathway.","date":"2022","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/35153498","citation_count":21,"is_preprint":false},{"pmid":"38695173","id":"PMC_38695173","title":"Deficiency of the Deubiquitinase UCHL1 Attenuates Pulmonary Arterial Hypertension.","date":"2024","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/38695173","citation_count":20,"is_preprint":false},{"pmid":"24124186","id":"PMC_24124186","title":"Cardiac sympathetic innervation and PGP9.5 expression by cardiomyocytes after myocardial infarction: effects of central MR blockade.","date":"2013","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24124186","citation_count":20,"is_preprint":false},{"pmid":"33137160","id":"PMC_33137160","title":"UCHL1 regulates oxidative activity in skeletal muscle.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33137160","citation_count":20,"is_preprint":false},{"pmid":"2403743","id":"PMC_2403743","title":"Detection of B- and T-cells in paraffin-embedded tissue sections. Diagnostic utility of commercially obtained 4KB5 and UCHL-1.","date":"1990","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/2403743","citation_count":20,"is_preprint":false},{"pmid":"28540657","id":"PMC_28540657","title":"UCH-L1 Inhibition Suppresses tau Aggresome Formation during Proteasomal Impairment.","date":"2017","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28540657","citation_count":20,"is_preprint":false},{"pmid":"33438509","id":"PMC_33438509","title":"UCHL1, a deubiquitinating enzyme, regulates lung endothelial cell permeability in vitro and in vivo.","date":"2021","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33438509","citation_count":20,"is_preprint":false},{"pmid":"34288216","id":"PMC_34288216","title":"UCHL1 regulates inflammation via MAPK and NF-κB pathways in LPS-activated macrophages.","date":"2021","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/34288216","citation_count":20,"is_preprint":false},{"pmid":"37215988","id":"PMC_37215988","title":"The deubiquitinase UCHL1 negatively controls osteoclastogenesis by regulating TAZ/NFATC1 signalling.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37215988","citation_count":19,"is_preprint":false},{"pmid":"8809066","id":"PMC_8809066","title":"Affinity purification and characterization of protein gene product 9.5 (PGP9.5) from retina.","date":"1996","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8809066","citation_count":19,"is_preprint":false},{"pmid":"30689542","id":"PMC_30689542","title":"UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors.","date":"2019","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30689542","citation_count":19,"is_preprint":false},{"pmid":"20104524","id":"PMC_20104524","title":"Silencing of the UCHL1 gene in giant cell tumors of bone.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20104524","citation_count":19,"is_preprint":false},{"pmid":"27671329","id":"PMC_27671329","title":"α-Chymotrypsin regulates free fatty acids and UCHL-1 to ameliorate N-methyl nitrosourea induced mammary gland carcinoma in albino wistar rats.","date":"2016","source":"Inflammopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27671329","citation_count":19,"is_preprint":false},{"pmid":"39612652","id":"PMC_39612652","title":"An automated blood test for glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) to predict the absence of intracranial lesions on head CT in adult patients with mild traumatic brain injury: BRAINI, a multicentre observational study in Europe.","date":"2024","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/39612652","citation_count":18,"is_preprint":false},{"pmid":"37507386","id":"PMC_37507386","title":"UCHL1 facilitates protein aggregates clearance to enhance neural stem cell activation in spinal cord injury.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37507386","citation_count":18,"is_preprint":false},{"pmid":"10721824","id":"PMC_10721824","title":"Expression of PGP9.5 on Langerhans' cells and their precursors.","date":"2000","source":"Acta dermato-venereologica","url":"https://pubmed.ncbi.nlm.nih.gov/10721824","citation_count":18,"is_preprint":false},{"pmid":"34745437","id":"PMC_34745437","title":"UCH-L1 and UCH-L3 regulate the cancer stem cell-like properties through PI3 K/Akt signaling pathway in prostate cancer cells.","date":"2021","source":"Animal cells and systems","url":"https://pubmed.ncbi.nlm.nih.gov/34745437","citation_count":18,"is_preprint":false},{"pmid":"23061666","id":"PMC_23061666","title":"UCHL1 regulates ubiquitination and recycling of the neural cell adhesion molecule NCAM.","date":"2012","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/23061666","citation_count":18,"is_preprint":false},{"pmid":"33159930","id":"PMC_33159930","title":"Abolishing UCHL1's hydrolase activity exacerbates TBI-induced axonal injury and neuronal death in mice.","date":"2020","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33159930","citation_count":18,"is_preprint":false},{"pmid":"38478109","id":"PMC_38478109","title":"Deubiquitinase UCHL1 promotes angiogenesis and blood-spinal cord barrier function recovery after spinal cord injury by stabilizing Sox17.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38478109","citation_count":17,"is_preprint":false},{"pmid":"35273370","id":"PMC_35273370","title":"Combined GFAP, NFL, Tau, and UCH-L1 panel increases prediction of outcomes in neonatal encephalopathy.","date":"2022","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/35273370","citation_count":17,"is_preprint":false},{"pmid":"28539953","id":"PMC_28539953","title":"Decreased Expression of α-Synuclein, Nogo-A and UCH-L1 in Patients with Schizophrenia: A Preliminary Serum Study.","date":"2017","source":"Psychiatry investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28539953","citation_count":17,"is_preprint":false},{"pmid":"37256780","id":"PMC_37256780","title":"UCHL1 aggravates skin fibrosis through an IGF-1-induced Akt/mTOR/HIF-1α pathway in keloid.","date":"2023","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/37256780","citation_count":16,"is_preprint":false},{"pmid":"36218038","id":"PMC_36218038","title":"Ubiquitin C-terminal hydrolase L1 (UCHL1), a double-edged sword in mammalian oocyte maturation and spermatogenesis.","date":"2022","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/36218038","citation_count":16,"is_preprint":false},{"pmid":"36434856","id":"PMC_36434856","title":"UCHL1 promotes cancer stemness in triple-negative breast cancer.","date":"2022","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/36434856","citation_count":16,"is_preprint":false},{"pmid":"31492742","id":"PMC_31492742","title":"Deubiquitinating Enzyme UCH-L1 Promotes Dendritic Cell Antigen Cross-Presentation by Favoring Recycling of MHC Class I Molecules.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/31492742","citation_count":16,"is_preprint":false},{"pmid":"38081437","id":"PMC_38081437","title":"UCHL1 deficiency upon HCMV infection induces vascular endothelial inflammatory injury mediated by mitochondrial iron overload.","date":"2023","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38081437","citation_count":16,"is_preprint":false},{"pmid":"32516975","id":"PMC_32516975","title":"Lessons on the Sigma-1 Receptor in TNBS-Induced Rat Colitis: Modulation of the UCHL-1, IL-6 Pathway.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32516975","citation_count":15,"is_preprint":false},{"pmid":"24583340","id":"PMC_24583340","title":"UCH-L1 induces podocyte hypertrophy in membranous nephropathy by protein accumulation.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24583340","citation_count":15,"is_preprint":false},{"pmid":"32987792","id":"PMC_32987792","title":"BDNF and IL-8, But Not UCHL-1 and IL-11, Are Markers of Brain Injury in Children Caused by Mild Head Trauma.","date":"2020","source":"Brain sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32987792","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54564,"output_tokens":11078,"usd":0.164931,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22053,"output_tokens":7839,"usd":0.15312,"stage2_stop_reason":"end_turn"},"total_usd":0.318051,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"UCH-L1 deubiquitinating activity is required for normal synaptic and cognitive function; restoration of UCH-L1 enzymatic activity (via TAT-UCH-L1 fusion protein) rescues beta-amyloid-induced decreases in synaptic function and restores normal levels of PKA-regulatory subunit IIalpha, PKA activity, and CREB phosphorylation in hippocampal slices and APP/PS1 mice.\",\n      \"method\": \"TAT-fusion protein transduction into hippocampal slices and APP/PS1 mice; enzymatic activity assays; biochemical measurement of PKA-RIIalpha, PKA activity, and CREB phosphorylation; contextual fear conditioning\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro enzyme activity restoration combined with in vivo behavioral rescue and multiple downstream pathway measurements in two independent AD models\",\n      \"pmids\": [\"16923396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"UCH-L1 (PGP9.5) interacts with JAB1 (a Jun activation domain-binding protein involved in p27Kip1 degradation) in vitro and in vivo, and both proteins form a heteromeric complex with p27Kip1 in the nucleus of lung cancer cells; nuclear translocation of UCH-L1 and JAB1 coincides with reduced nuclear p27Kip1 levels, suggesting UCH-L1 contributes to p27Kip1 degradation via JAB1.\",\n      \"method\": \"Yeast two-hybrid screen; co-immunoprecipitation in vitro and in vivo; colocalization studies; serum restimulation and contact inhibition experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reciprocal Co-IP and colocalization in multiple cell contexts, single lab, no reconstituted degradation assay\",\n      \"pmids\": [\"12082530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"UCH-L1 regulates the balance between mTORC1 and mTORC2 by disrupting the DDB1-CUL4 ubiquitin ligase complex interaction with raptor and counteracting DDB1-CUL4-mediated raptor ubiquitination, leading to mTORC1 dissolution and secondary increase in mTORC2 activity (increased Akt phosphorylation, decreased S6K and 4EBP1 phosphorylation).\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays; mTOR complex assembly analysis; UCHL1-deficient and transgenic mouse models; kinase activity assays for S6K, 4EBP1, and Akt\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ubiquitination assay, genetic mouse models, multiple orthogonal methods in one study demonstrating mechanistic rearrangement of mTOR complexes\",\n      \"pmids\": [\"23297343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Familial PD-associated I93M mutant UCH-L1 and carbonyl-modified (oxidatively damaged) UCH-L1 share aberrant properties: increased insolubility, elevated interactions with multiple proteins including tubulin, and similar structural changes by circular dichroism; aberrant interaction of mutant or carbonyl-modified UCH-L1 with tubulin modulates tubulin polymerization.\",\n      \"method\": \"Circular dichroism analysis; solubility fractionation; co-immunoprecipitation/pulldown with tubulin; in vitro tubulin polymerization assay; transgenic mice\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro biochemical assays (CD, polymerization) plus co-IP, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"18250096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"UCH-L1 associates with and promotes assembly of the translation initiation complex eIF4F and stimulates protein synthesis through a mechanism requiring its catalytic (deubiquitinase) activity; this bypasses mTORC1-dependent protein synthesis and is required for MYC-driven lymphomagenesis in Eμ-myc mice.\",\n      \"method\": \"Proximity-based proteomics (BioID); co-immunoprecipitation; protein synthesis assays; catalytic mutant UCH-L1 transgenic mice; Eμ-myc lymphoma model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — proximity proteomics plus genetic mouse model plus catalytic mutant requirement, multiple orthogonal methods, direct functional readout\",\n      \"pmids\": [\"30257881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"UCH-L1 displays distinct substrate recognition from its homologue UCH-L3; specific ubiquitin side chains critical for forming the Michaelis complex and enabling catalysis by UCH-L1 were identified using a panel of ubiquitin fusions; activation parameters show mechanistic differences in substrate specificity between UCH-L1 and UCH-L3.\",\n      \"method\": \"In vitro enzymatic assays with ubiquitin fusion panel; kinetic analysis; activation parameter measurements\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro kinetic and mechanistic characterization with multiple substrate variants, single lab but rigorous quantitative biochemistry\",\n      \"pmids\": [\"17144664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Crystal structure of UCHL1 in complex with inhibitor GK13S reveals the enzyme locked in a hybrid conformation between apo and ubiquitin-bound states; stereoselective inhibition of cellular UCHL1 by GK13S reduces monoubiquitin levels in glioblastoma cells, phenocopying an inactivating mouse mutation of UCHL1.\",\n      \"method\": \"X-ray crystallography; biochemical characterization of activity-based probes; cellular monoubiquitin measurement; activity-based probe labeling\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with functional validation, stereoselective probe pair, cellular monoubiquitin phenocopy of genetic inactivation, multiple methods\",\n      \"pmids\": [\"36216817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"UCH-L1 directly deubiquitinates TrkB (the BDNF receptor) at lysine K460 in the juxtamembrane domain; UCH-L1-regulated TrkB deubiquitination prevents BDNF-induced TrkB internalization and lysosomal degradation, sustaining surface TrkB levels, TrkB activation, and downstream signaling; blocking UCH-L1–TrkB interaction in vivo impairs hippocampus-dependent memory.\",\n      \"method\": \"Co-immunoprecipitation; in vitro deubiquitination assay; ubiquitination site mapping (K460); competitive inhibitory peptide; in vivo hippocampal injection and fear conditioning\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct deubiquitination assay, site-specific mutagenesis of K460, competitive peptide inhibition both in vitro and in vivo, behavioral readout\",\n      \"pmids\": [\"28500221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"UCHL1 binds, deubiquitinates, and stabilizes EGFR (epidermal growth factor receptor), thereby activating downstream EGFR mediators and driving pathological cardiac hypertrophy; knockdown of UCHL1 ameliorates hypertrophy while overexpression exacerbates it.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assay; UCHL1 knockdown and overexpression in cardiomyocytes; rAAV9-UCHL1 mouse model; pressure overload model; pharmacological inhibition with LDN-57444\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ubiquitination assay, genetic gain/loss-of-function in cells and two in vivo models, pharmacological validation\",\n      \"pmids\": [\"32494592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"UCHL1 deubiquitinates and stabilizes EGFR, which suppresses ERα transcription, thereby downregulating estrogen receptor alpha expression in breast cancer; UCH-L1 inhibition restores ERα expression and sensitizes ER-negative breast cancer to tamoxifen and fulvestrant in vivo and in vitro.\",\n      \"method\": \"Immunoprecipitation; ubiquitination assay; luciferase reporter; ChIP assay; qRT-PCR; immunoblotting; in vivo xenograft model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, ChIP, and in vivo data, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"32042339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"UCH-L1 protects from TNF-induced necroptosis; HtrA2/Omi serine protease induces monoubiquitination of UCH-L1 (indicative of activation) during necroptosis rather than cleaving it; pharmacological or RNAi-mediated inhibition of UCH-L1 protects cells from TNF-induced necroptosis; UCH-L1 is a mediator of caspase-independent cell death in kidney podocytes.\",\n      \"method\": \"Pharmacological inhibition; RNA interference; cell death assays; monoubiquitination detection; PARP-1 cleavage; caspase activity assays; morphological analysis\",\n      \"journal\": \"Cell communication and signaling : CCS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — RNAi plus pharmacological inhibition in multiple cell systems, detection of UCH-L1 monoubiquitination, single lab\",\n      \"pmids\": [\"24090154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"UCHL1 promotes podocyte necroptosis by maintaining deubiquitinated (stabilized) RIPK1 and RIPK3; UCHL1 knockdown reduces half-life and expression of RIPK1 and RIPK3, decreasing MLKL activation and protecting podocytes from high-glucose-induced necroptosis.\",\n      \"method\": \"UCHL1 siRNA knockdown; protein half-life assay; Western blot for RIPK1, RIPK3, MLKL, caspase-3; cell death assays; scanning electron microscopy; in vivo diabetic nephropathy model\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — knockdown with defined molecular phenotype (protein stability of RIPK1/RIPK3), in vivo model, single lab\",\n      \"pmids\": [\"31247189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Binding of ischemia-induced reactive lipid species to cysteine C152 of UCHL1 inactivates the enzyme; a C152A knock-in mouse resistant to lipid adduction showed decreased axonal injury, reduced tissue loss, preserved excitatory synaptic drive and axonal conduction velocity, and improved sensorimotor recovery after MCAO, demonstrating that C152 is a key site for post-translational inactivation of UCHL1 by reactive lipids after stroke.\",\n      \"method\": \"C152A knock-in mouse; middle cerebral artery occlusion (MCAO); histological analysis; electrophysiology; behavioral assessment; polyubiquitinated protein detection\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in mouse with site-specific mutation, multiple in vivo and ex vivo functional readouts, direct identification of the PTM site\",\n      \"pmids\": [\"30760601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"UCHL1 deubiquitinates and stabilizes pyruvate kinase (PKM), promoting glycolysis; loss of UCHL1 destabilizes PKM, reduces pyruvate and ATP levels, activates AMPK, and promotes AMPK-dependent mitophagy via ULK1 and FUNDC1, mitigating PD-related phenotypes caused by PINK1/Parkin loss-of-function. TRIM63 is identified as the E3 ligase for PKM, antagonizing UCHL1.\",\n      \"method\": \"UCHL1 knockout cells and Drosophila models; PKM stability assay; ATP/pyruvate measurements; AMPK activity assay; mitophagy assays; co-immunoprecipitation; E3 ligase identification\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic models in two organisms plus biochemical substrate validation and E3 ligase identification, multiple orthogonal assays\",\n      \"pmids\": [\"34244144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"UCH-L1 interacts with and promotes K63-linked ubiquitin chain formation on tau, and its inhibition reduces K63-linked ubiquitin chains, decreases HDAC6 deacetylase activity, attenuates HDAC6–tau interaction, and impairs proteasomal impairment-induced tau aggresome formation.\",\n      \"method\": \"UCH-L1 inhibitor (LDN); UCH-L1 siRNA; immunoprecipitation; ubiquitin chain-linkage analysis; HDAC6 activity assay; tau aggresome immunofluorescence\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — pharmacological inhibitor and siRNA with mechanistic follow-up on K63 chains and HDAC6 activity, single lab\",\n      \"pmids\": [\"28540657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"UCH-L1 inhibition decreases the microtubule-binding ability of tau and increases tau phosphorylation and abnormal ubiquitination; both pharmacological inhibition of UCH-L1 activity (LDN) and siRNA-mediated knockdown produce these effects in neuronal cell lines.\",\n      \"method\": \"UCH-L1 inhibitor LDN; UCH-L1 siRNA in HEK293/tau441 cells; tau-microtubule binding assay; immunofluorescence; immunoprecipitation; phosphorylation analysis\",\n      \"journal\": \"Journal of Alzheimer's disease : JAD\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct tau-microtubule binding assay with two independent loss-of-function approaches, single lab\",\n      \"pmids\": [\"26444754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"UCHL1 interacts with NCAM180 (and NCAM140) isoforms of the neural cell adhesion molecule; overexpression of UCHL1 decreases constitutive ubiquitination of NCAM180 and NCAM140 and reduces their lysosomal localization, indicating UCHL1 regulates NCAM ubiquitination and intracellular trafficking/recycling.\",\n      \"method\": \"Protein macroarray screening; co-immunoprecipitation; colocalization in primary neurons; UCHL1 overexpression and inhibition; ubiquitination assays; lysosomal trafficking assays\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — macroarray plus Co-IP plus functional ubiquitination and trafficking assays, single lab\",\n      \"pmids\": [\"23061666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"UCHL-1 is aberrantly recruited to mitochondria by NH2-terminal tau fragment (NH2htau) in neurons; shRNA-mediated silencing of UCHL-1 (or Parkin) suppresses excessive mitophagy induced by NH2htau, restores synaptic and mitochondrial content, and provides partial protection against NH2htau-induced neuronal death; endogenous NH2htau is associated with UCHL-1 and Parkin in mitochondria from human AD synapses.\",\n      \"method\": \"shRNA silencing of UCHL-1; mitophagy assays; mitochondrial fractionation; co-immunoprecipitation from human AD synaptic mitochondria; cell viability assays; primary hippocampal neurons\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — shRNA knockdown in neurons with functional readouts plus human AD tissue co-IP validation, single lab\",\n      \"pmids\": [\"25687137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"UCHL1 deubiquitinates CD36 (a scavenger receptor), stabilizing it and promoting oxidized LDL uptake and foam cell formation; UCHL1 inhibition or deletion increases K48-polyubiquitination of CD36 and reduces its protein levels, decreasing lipid accumulation.\",\n      \"method\": \"UCHL1 siRNA; UCHL1 inhibitor; ubiquitination assay for CD36; Western blot; lipid uptake assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ubiquitination assay plus two independent loss-of-function approaches with defined substrate (CD36), single lab\",\n      \"pmids\": [\"32801299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"UCHL1 interacts with IκBα protein and inhibits its K48-linked ubiquitination and proteasomal degradation; UCHL1 inhibition blocks LPS-induced IκBα degradation, suppresses NF-κB nuclear translocation, reduces ERK1/2 phosphorylation, and decreases pro-inflammatory cytokine production in macrophages.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assay; UCHL1 inhibitor; Western blot for IκBα, phospho-ERK1/2, NF-κB; ELISA for IL-6 and TNF-α; in vivo LPS model\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct Co-IP with IκBα, ubiquitination assay, pharmacological inhibition with in vivo validation, single lab\",\n      \"pmids\": [\"34288216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"UCHL1 regulates mTORC1 and mTORC2 balance in skeletal muscle; skeletal muscle-specific knockout of UCHL1 increases mTORC1 activity and decreases mTORC2 activity in slow-twitch (soleus) but not fast-twitch (EDL) muscle, leading to enlarged slow-twitch muscle fibers; UCHL1 knockdown decreases PRAS40 protein turnover, contributing to increased mTORC1 activity.\",\n      \"method\": \"Skeletal muscle-specific UCHL1 knockout mice; C2C12 siRNA knockdown; mTORC1/2 activity assays (phosphorylation of downstream targets); fiber type staining; PRAS40 protein turnover assay\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific knockout plus cell-based knockdown with consistent mTOR complex phenotype, single lab\",\n      \"pmids\": [\"31356902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"UCHL1 hydrolase activity is required for normal axonal conduction and protection after traumatic brain injury; C90A knock-in mice (devoid of hydrolase activity) show increased axonal injury, greater hippocampal neuron loss, elevated polyubiquitinated proteins and Beclin-1 after controlled cortical impact, suggesting the hydrolase activity maintains UPS function and suppresses autophagy after TBI.\",\n      \"method\": \"C90A hydrolase-dead knock-in mouse; controlled cortical impact TBI model; histology; immunohistochemistry for APP and SMI-32; polyubiquitin and Beclin-1 Western blot; behavioral beam balance test\",\n      \"journal\": \"Experimental neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in mouse with site-specific active-site mutation, multiple histological and molecular readouts in vivo, direct attribution of hydrolase activity to axonal protection\",\n      \"pmids\": [\"33159930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"UCHL1 interacts with the NACHT domain of NLRP3 inflammasome; UCH-L1 downregulation decreases pro-IL-1β levels; pharmacological UCH-L1 inhibition interferes with NLRP3 puncta formation and ASC oligomerization, reducing IL-1β cleavage and secretion particularly in microglia.\",\n      \"method\": \"Proximity labeling (affinity purification); RNAi screening; co-immunoprecipitation; NLRP3 puncta imaging; ASC oligomerization assay; UCHL1 chemical inhibition; IL-1β ELISA\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — proximity labeling plus direct Co-IP of UCHL1–NLRP3, pharmacological and genetic validation, single study\",\n      \"pmids\": [\"38669140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Uch-L1 and Uch-L3 have both separate and overlapping functions in maintaining axonal integrity: double Uch-L1/Uch-L3 knockout mice display earlier lethality, dysphagia, and more severe axonal degeneration of the gracile tract, nucleus tractus solitarius, and area postrema than either single knockout, demonstrating redundant and distinct roles in neuronal maintenance.\",\n      \"method\": \"Uch-L1/Uch-L3 double-knockout mouse generation; histological analysis of axonal degeneration; behavioral and survival analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via double-knockout mouse with clear quantitative neurodegeneration phenotypes, establishes functional redundancy and distinct roles\",\n      \"pmids\": [\"11555633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"UCHL1 deubiquitinates and stabilizes Sox17 in endothelial cells; conditional UCHL1 knockout impairs endothelial cell proliferation, migration, tube formation, angiogenesis, and blood-spinal cord barrier recovery after spinal cord injury, while UCHL1 overexpression promotes these processes.\",\n      \"method\": \"Immunoprecipitation-mass spectrometry; co-immunoprecipitation; conditional UCHL1 knockout mice; Sox17 knockdown/overexpression; in vitro endothelial cell assays; in vivo SCI model\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — IP-MS identification plus Co-IP validation, conditional KO mice with functional rescue, single lab\",\n      \"pmids\": [\"38478109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"UCHL1 stabilizes PFKFB3 (a glycolytic regulator) in astrocytes by cleaving K48-linked ubiquitin chains; UCHL1/PFKFB3 axis increases lactate production, leading to histone H4K8 lactylation and subsequent transcriptional upregulation of Uchl1 and glycolysis genes, forming a positive feedback loop that sustains astrocytic glycolytic reprogramming and prevents neuronal ferroptosis after spinal cord injury.\",\n      \"method\": \"Genetic Uchl1 deletion; PFKFB3 knockout; K48-linked ubiquitination assay; histone lactylation assay; co-immunoprecipitation; scRNA-seq analysis; in vivo SCI model\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ubiquitination assay plus genetic models plus histone lactylation measurement, single lab, multiple methods\",\n      \"pmids\": [\"40016338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RANKL stimulates UCHL1 expression in osteoclast precursors; UCHL1 stabilizes CD13 (deubiquitinates it), augmenting soluble CD13 (sCD13) release, which exerts an autocrine inhibitory effect on the MAPK pathway to suppress osteoclast formation; conditional UCHL1 deletion in osteoclast precursors exacerbates OA while overexpression alleviates it.\",\n      \"method\": \"Conditional UCHL1 knockout mice; AAV9-UCHL1 overexpression; osteoclast differentiation assays; co-immunoprecipitation; ubiquitination assay for CD13; MAPK pathway analysis; human and murine OA specimens\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout plus viral overexpression in vivo, direct ubiquitination of substrate CD13, defined autocrine signaling mechanism, two species validation\",\n      \"pmids\": [\"39389988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"UCHL1 deubiquitinates and stabilizes TAZ at K46 (removing K48-linked polyubiquitin); stabilized TAZ competes with calcineurin A (CNA) for binding to NFATC1, inhibiting NFATC1 dephosphorylation and nuclear transport, thereby suppressing osteoclastogenesis; osteoclast-specific UCHL1 knockout mice develop severe osteoporosis.\",\n      \"method\": \"Osteoclast-specific conditional UCHL1 knockout mice; co-immunoprecipitation; in vitro ubiquitination/deubiquitination assay; K46 mutagenesis; NFATC1 nuclear transport assay; ovariectomy bone loss model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — site-specific K46 mutagenesis, reconstituted deubiquitination assay, conditional knockout in vivo, mechanistic competition assay for NFATC1\",\n      \"pmids\": [\"37215988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"UCHL1 binds, deubiquitinates, and stabilizes HIF-1α following myocardial infarction; UCHL1 knockout cardiomyocytes (via CRISPR/Cas9 in hiPSCs) show reduced HIF-1α expression and suppressed HIF-1α target genes; recombinant UCHL1 and AAV9-cardiac UCHL1 delivery protect against MI in mice.\",\n      \"method\": \"BioID proximity labeling + mass spectrometry; CRISPR/Cas9 UCHL1 knockout hiPSC-derived cardiomyocytes; Western blot for HIF-1α; HIF-1α target gene qRT-PCR; recombinant UCHL1 IP injection; AAV9-UCHL1 cardiac delivery; MI mouse model\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BioID plus genetic KO plus in vivo AAV delivery, direct HIF-1α stabilization demonstrated, single lab\",\n      \"pmids\": [\"35339825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"UCH-L1 regulates lung endothelial barrier function; UCHL1 knockdown or pharmacological inhibition (LDN-57444) decreases VE-cadherin and claudin-5 expression, reduces barrier enhancement by HGF, and increases thrombin-induced permeability; silencing FoxO1 transcription factor restores claudin-5 levels; UCHL1 inhibition in vivo increases ventilator-induced lung injury.\",\n      \"method\": \"UCHL1 siRNA; LDN-57444 inhibitor; transendothelial electrical resistance; VE-cadherin and claudin-5 Western blot; FoxO1 siRNA rescue; murine VILI model\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — pharmacological and genetic inhibition with mechanistic rescue experiment, in vivo validation, single lab\",\n      \"pmids\": [\"33438509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"UCHL1 deficiency attenuates pulmonary arterial hypertension via reduction of AKT1; UCHL1 deubiquitinates AKT1 (specifically promotes K63-linked and reduces K48-linked ubiquitination), maintaining higher AKT1 levels; Uchl1 knockout rats and conditional Uchl1 knockout mice show reduced right ventricular hypertrophy, pressure, and vascular remodeling.\",\n      \"method\": \"UCHL1-silenced human pulmonary artery endothelial cells; Uchl1 knockout rats; conditional Uchl1 knockout mice (Tie2Cre); LDN57444 pharmacological inhibition; K63/K48-ubiquitinated Akt detection; right ventricular hemodynamics; vascular histology; three preclinical PAH models\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple independent genetic models (rat KO, conditional mouse KO, siRNA) plus pharmacological inhibition, K63/K48-ubiquitination assay defines mechanism, three PAH models\",\n      \"pmids\": [\"38695173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"UCHL1 binds, deubiquitinates, and stabilizes POM121 (a nuclear pore complex nucleoporin); stabilized POM121 regulates nuclear transport of E2F1 and c-MYC, maintaining neuroendocrine differentiation and promoting cancer progression in neuroendocrine carcinomas.\",\n      \"method\": \"Co-immunoprecipitation; deubiquitination assay; loss-of-function (siRNA/UCHL1 KO); nuclear fractionation for E2F1 and c-MYC; in vivo tumor growth and metastasis assays; UCHL1 inhibitor LDN-57444\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and deubiquitination assay, nuclear transport assay, in vivo models, single lab\",\n      \"pmids\": [\"38244540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"UCHL1 interacts with, deubiquitylates, and stabilizes ferredoxin reductase (FDXR), an important mitochondrial iron homeostasis protein; HCMV infection-induced loss of UCHL1 causes FDXR ubiquitination and degradation, leading to mitochondrial iron overload, AIM2 inflammasome activation, and vascular endothelial inflammatory injury.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assay for FDXR; UCHL1 knockdown; HCMV infection model; mitochondrial iron measurement; AIM2 inflammasome activation assay; MCMV-infected mice\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP with deubiquitination assay, in vivo mouse model validation, single lab\",\n      \"pmids\": [\"38081437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"UCH-L1 promotes cross-presentation of antigens by dendritic cells by facilitating MHC class I molecule recycling; UCH-L1-deficient DCs have reduced ability to generate MHC I–peptide complexes and to cross-prime CD8 T cells in vivo; antigen uptake and phagosome maturation are unaffected, while intracellular MHC I colocalization with late endosomal/lysosomal compartments is reduced.\",\n      \"method\": \"UCH-L1-deficient mice; in vivo and in vitro CD8 T cell cross-priming assays; MHC I recycling assay; phagocytosis and phagosome maturation assays; MHC I colocalization imaging\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with in vivo and in vitro functional assays, mechanistic exclusion of upstream steps and identification of MHC I recycling as the step regulated by UCHL1, single lab\",\n      \"pmids\": [\"31492742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"UCH-L1 activity increases podocyte hypertrophy and total protein content in membranous nephropathy; mechanistically, UCH-L1 increases cytoplasmic p27Kip1 by promoting its nuclear export and decreasing its poly-ubiquitination and proteasomal degradation; inhibition of UCH-L1 attenuates podocyte hypertrophy.\",\n      \"method\": \"UCH-L1 overexpression and knockdown in podocytes; UCH-L1 inhibitor; p27Kip1 nuclear/cytoplasmic fractionation; ubiquitination assay for p27Kip1; protein content measurement; human and rat MGN tissue analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — gain and loss of function with mechanistic ubiquitination and localization assay for defined substrate p27Kip1, single lab\",\n      \"pmids\": [\"24583340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"UCH-L1 absence causes pure motor neuropathy with selective degeneration of motor (not sensory) axons; neuromuscular junctions are impaired in both slow- and fast-twitch muscle groups but spinal motor neuron cell bodies remain intact without signs of ER stress, indicating UCHL1 is specifically required for NMJ and motor axon maintenance rather than motor neuron survival.\",\n      \"method\": \"Uchl1(nm3419) UCHL1-/- mice; molecular and cellular marker expression analysis; electrophysiological recordings; NMJ morphological analysis; axon and sensory neuron histology\",\n      \"journal\": \"Annals of clinical and translational neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — defined genetic null mouse with comprehensive cellular and electrophysiological phenotyping distinguishing motor vs sensory axons and cell bodies\",\n      \"pmids\": [\"27231703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"UCHL1 promotes HGSOC (high-grade serous ovarian cancer) growth by maintaining protein homeostasis via the PSMA7-APEH-proteasome axis; UCHL1 silencing reduces PSMA7 and APEH expression and proteasome activity, causes polyubiquitinated protein accumulation, attenuates mTORC1 activity and protein synthesis, and induces terminal UPR.\",\n      \"method\": \"UCHL1 siRNA in HGSOC cells; in vivo xenograft metastasis model; transcriptional profiling; PSMA7 and APEH knockdown; proteasome activity assay; polyubiquitin accumulation; mTORC1 signaling assay\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — siRNA with in vivo xenograft, mechanistic cascade (PSMA7-APEH-proteasome) defined by sequential knockdown, single lab\",\n      \"pmids\": [\"33753553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NF-κB transcription factor binds the UCH-L1 promoter at –300 bp and –109 bp sites and upregulates UCH-L1 expression; TNF-α and IL-1β cytokine stimulation of podocytes activates NF-κB and rapidly increases UCH-L1 mRNA and protein, while NF-κB inhibition (PDTC) prevents this upregulation.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA); promoter reporter analysis; NF-κB inhibitor (PDTC); cytokine stimulation of podocytes; Western blot and qRT-PCR; immunohistochemistry of human lupus nephritis biopsies\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA demonstrating direct NF-κB–promoter binding plus pharmacological inhibition, single lab\",\n      \"pmids\": [\"23567262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"UCH-L1 promotes breast cancer cell invasion by interacting preferentially with Akt2 and activating Akt signaling; proximity-dependent BioID identified UCH-L1–Akt interaction, confirmed by pulldown with His-tagged recombinant UCH-L1 from cell lysate; UCH-L1 overexpression increases phosphorylated Akt while knockdown suppresses invasion.\",\n      \"method\": \"BioID proximity labeling; streptavidin pulldown; His-tagged recombinant UCH-L1 pulldown; phospho-Akt Western blot; invasion assays; UCH-L1 siRNA\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — BioID plus recombinant pulldown confirming Akt2 interaction, functional invasion readout, single lab\",\n      \"pmids\": [\"28636190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"PGP9.5/UCH-L1 was purified to homogeneity from bovine retina by ubiquitin-Sepharose affinity chromatography; the purified protein displays hydrolytic activity on ubiquitin ethyl ester (UbOEt) and reactivity with cysteine and histidine-specific reagents, confirming it is a cysteine/histidine-dependent ubiquitin C-terminal hydrolase with biochemical properties distinguishable from other UCH family members.\",\n      \"method\": \"Ubiquitin-Sepharose affinity chromatography; enzymatic assay with UbOEt; cysteine/histidine reagent inhibition; Km determination\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical purification and enzymatic characterization of the native protein, establishes catalytic mechanism\",\n      \"pmids\": [\"8809066\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"UCHL1 is a neuronal-abundant deubiquitinating enzyme (cysteine/histidine-dependent UCH family) that maintains free ubiquitin homeostasis and directly deubiquitinates and stabilizes multiple substrates—including TrkB, EGFR, HIF-1α, PKM, POM121, TAZ, CD13, CD36, AKT1, FDXR, PFKFB3, Sox17, RIPK1, RIPK3, and raptor—to regulate synaptic plasticity, axonal integrity, mTOR complex balance (disrupting mTORC1/promoting mTORC2), translation initiation (eIF4F assembly), cardiac and pulmonary hypertrophy, immune signaling (NF-κB via IκBα; NLRP3 inflammasome; MHC I recycling in dendritic cells), glycolysis, osteoclastogenesis, and necroptosis; its catalytic cysteine C152 is a critical site of inactivation by reactive lipids generated during ischemia, and loss of its hydrolase activity impairs UPP function and worsens axonal injury after brain trauma.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"UCHL1 is a neuronal-abundant, cysteine/histidine-dependent ubiquitin C-terminal hydrolase whose catalytic activity maintains free ubiquitin homeostasis and supports neuronal and synaptic integrity [#39, #6, #23]. Biochemically it is a deubiquitinating enzyme distinguishable from its homologue UCH-L3 by distinct substrate recognition, and structural work captures it in a hybrid conformation between apo and ubiquitin-bound states whose inhibition lowers cellular monoubiquitin, phenocopying genetic inactivation [#5, #6]. Genetic loss of UCHL1 alone or together with UCH-L3 produces progressive axonal degeneration, and selective motor axon and neuromuscular-junction failure, establishing its role in neuronal maintenance rather than neuron survival [#23, #35]. Across many cell types UCHL1 acts as a substrate-stabilizing DUB: it deubiquitinates and stabilizes TrkB to sustain BDNF signaling and memory, EGFR to drive cardiac hypertrophy and ER-negative breast cancer, HIF-1\\u03b1 after myocardial infarction, AKT1 in pulmonary hypertension, and metabolic and trafficking substrates including PKM, PFKFB3, CD36, CD13, POM121, Sox17, and FDXR [#7, #8, #9, #28, #30, #13, #25, #18, #26, #31, #24, #32]. Through these substrates UCHL1 regulates glycolytic reprogramming, mitophagy, mTOR complex balance, and endothelial barrier and angiogenic function [#13, #2, #24, #29]. It also restrains necroptosis by stabilizing RIPK1/RIPK3, modulates NF-\\u03baB and NLRP3 inflammasome signaling in myeloid cells, and promotes MHC class I recycling for dendritic-cell cross-presentation [#11, #19, #22, #33]. Its catalytic activity is itself a regulated node: the active-site cysteine C152 is inactivated by ischemia-generated reactive lipids, and hydrolase-dead knock-in mice show worsened axonal injury after trauma, linking loss of UCHL1 catalysis to impaired ubiquitin-proteasome function [#12, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established the biochemical identity of UCHL1 as a catalytic enzyme, defining the mechanistic basis for all subsequent functional work.\",\n      \"evidence\": \"Affinity purification of native PGP9.5/UCH-L1 from bovine retina with enzymatic and active-site reagent characterization\",\n      \"pmids\": [\"8809066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular substrates not addressed\", \"Physiological role undefined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Answered whether UCHL1 is required for neuronal maintenance by showing genetic loss causes axonal degeneration with partial redundancy to UCH-L3.\",\n      \"evidence\": \"Uch-L1/Uch-L3 double-knockout mice with histological axonal phenotyping\",\n      \"pmids\": [\"11555633\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular substrates driving degeneration not identified\", \"Mechanism of redundancy unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"First interactor work linking UCHL1 to cell-cycle control via JAB1 and p27Kip1 in a nuclear complex.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal Co-IP and colocalization in lung cancer cells\",\n      \"pmids\": [\"12082530\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No reconstituted degradation assay\", \"Direct DUB activity on p27Kip1 not shown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated that UCHL1 enzymatic activity is functionally required for synaptic plasticity and memory, connecting its DUB activity to PKA/CREB signaling.\",\n      \"evidence\": \"TAT-UCH-L1 transduction and rescue in hippocampal slices and APP/PS1 mice with behavioral readout\",\n      \"pmids\": [\"16923396\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct synaptic substrate not identified\", \"Mechanism linking DUB activity to PKA-RIIalpha unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined the mechanistic basis of UCHL1 substrate specificity distinct from UCH-L3 at the level of Michaelis-complex formation.\",\n      \"evidence\": \"In vitro kinetics with a ubiquitin fusion panel\",\n      \"pmids\": [\"17144664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrates not tested\", \"No structural correlate at the time\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Connected PD-associated and oxidatively damaged UCHL1 to a gain of aberrant tubulin interaction, providing a toxicity mechanism.\",\n      \"evidence\": \"Circular dichroism, solubility fractionation, tubulin pulldown and polymerization assays in transgenic mice\",\n      \"pmids\": [\"18250096\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Causal link to neurodegeneration in vivo incomplete\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed that UCHL1 reorganizes mTOR complex balance by counteracting DDB1-CUL4-mediated raptor ubiquitination, shifting activity from mTORC1 to mTORC2.\",\n      \"evidence\": \"Co-IP, ubiquitination assays and genetic mouse models with kinase activity readouts\",\n      \"pmids\": [\"23297343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether raptor is a direct DUB substrate vs ligase disruption not fully separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established UCHL1 as a pro-necroptotic factor activated by monoubiquitination during TNF-induced caspase-independent death.\",\n      \"evidence\": \"RNAi and pharmacological inhibition with monoubiquitination detection in podocytes\",\n      \"pmids\": [\"24090154\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct necroptotic substrate not identified in this study\", \"Single lab\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined transcriptional control of UCHL1 by NF-\\u03baB, embedding it in inflammatory signaling loops.\",\n      \"evidence\": \"EMSA, promoter reporter and NF-\\u03baB inhibition in cytokine-stimulated podocytes\",\n      \"pmids\": [\"23567262\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Other transcriptional regulators not excluded\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed UCHL1 stabilizes cytoplasmic p27Kip1 by promoting nuclear export and reducing its ubiquitination, driving podocyte hypertrophy.\",\n      \"evidence\": \"Gain/loss of function with fractionation and ubiquitination assays in podocytes and disease tissue\",\n      \"pmids\": [\"24583340\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect deubiquitination of p27Kip1 not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified TrkB as a direct UCHL1 substrate, explaining how UCHL1 sustains BDNF signaling and memory by preventing receptor degradation.\",\n      \"evidence\": \"In vitro deubiquitination, K460 site mapping and competitive peptide with in vivo behavioral readout\",\n      \"pmids\": [\"28500221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Recruitment of UCHL1 to TrkB unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked UCHL1 activity to tau microtubule binding and phosphorylation, implicating it in cytoskeletal/aggregation pathways.\",\n      \"evidence\": \"Inhibitor and siRNA in neuronal cells with tau-microtubule binding assays\",\n      \"pmids\": [\"26444754\", \"28540657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether tau is a direct substrate not shown\", \"K63-chain mechanism via HDAC6 single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected UCHL1 to excessive mitophagy when aberrantly recruited to mitochondria by an N-terminal tau fragment.\",\n      \"evidence\": \"shRNA silencing with mitophagy and viability assays plus human AD synaptic mitochondria Co-IP\",\n      \"pmids\": [\"25687137\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of mitochondrial recruitment unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed UCHL1 promotes eIF4F assembly and protein synthesis independent of mTORC1, a catalytic-activity-dependent route required for MYC-driven lymphoma.\",\n      \"evidence\": \"BioID, Co-IP, protein synthesis assays and catalytic-mutant mice in Eu-myc model\",\n      \"pmids\": [\"30257881\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct DUB substrate within eIF4F not pinpointed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended mTOR-balance regulation to skeletal muscle, with PRAS40 turnover as a contributing node.\",\n      \"evidence\": \"Muscle-specific knockout and C2C12 knockdown with mTORC1/2 readouts\",\n      \"pmids\": [\"31356902\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Fiber-type selectivity mechanism unexplained\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a role in dendritic-cell cross-presentation by promoting MHC class I recycling rather than uptake or phagosome maturation.\",\n      \"evidence\": \"UCHL1-deficient mice with cross-priming, recycling and colocalization assays\",\n      \"pmids\": [\"31492742\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular substrate controlling recycling not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established UCHL1 maintenance of endothelial barrier integrity via junctional protein expression and a FoxO1 axis.\",\n      \"evidence\": \"siRNA and LDN-57444 with TEER, junction protein blots, FoxO1 rescue and VILI model\",\n      \"pmids\": [\"33438509\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct substrate linking UCHL1 to claudin-5/FoxO1 unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified RIPK1/RIPK3 as stability-dependent effectors through which UCHL1 promotes podocyte necroptosis.\",\n      \"evidence\": \"siRNA with protein half-life and MLKL activation assays plus diabetic nephropathy model\",\n      \"pmids\": [\"31247189\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct deubiquitination of RIPK1/RIPK3 not formally demonstrated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Determined that ischemia-generated reactive lipids inactivate UCHL1 at C152, identifying a stroke-relevant post-translational off-switch.\",\n      \"evidence\": \"C152A knock-in mice with MCAO, electrophysiology and behavior\",\n      \"pmids\": [\"30760601\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of all relevant lipid adducts not catalogued\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified EGFR as a UCHL1 substrate driving pathological cardiac hypertrophy and, separately, ER\\u03b1 suppression in breast cancer.\",\n      \"evidence\": \"Reciprocal Co-IP, ubiquitination assays, in vivo cardiac and xenograft models, pharmacological inhibition\",\n      \"pmids\": [\"32494592\", \"32042339\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity of UCHL1 among receptor pools unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed UCHL1 stabilizes CD36 to promote oxLDL uptake and foam-cell formation.\",\n      \"evidence\": \"siRNA, inhibitor and CD36 ubiquitination assays with lipid uptake readout\",\n      \"pmids\": [\"32801299\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"In vivo atherosclerosis confirmation limited\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated hydrolase activity per se is required for axonal protection after TBI via maintenance of proteasome function.\",\n      \"evidence\": \"C90A hydrolase-dead knock-in mice in controlled cortical impact model\",\n      \"pmids\": [\"33159930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific accumulated substrates after TBI not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected UCHL1 to glycolysis/mitophagy via PKM stabilization, with TRIM63 as the antagonist E3 ligase, mitigating PD-related phenotypes.\",\n      \"evidence\": \"Knockout cells and Drosophila, PKM stability assays, AMPK/mitophagy readouts and E3 identification\",\n      \"pmids\": [\"34244144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality across neuronal subtypes untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined an anti-inflammatory role through stabilization of I\\u03baB\\u03b1 and restraint of NF-\\u03baB in macrophages.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, inhibitor and in vivo LPS model\",\n      \"pmids\": [\"34288216\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Apparent context-dependence vs pro-inflammatory roles unreconciled\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed UCHL1 sustains proteostasis in ovarian cancer through a PSMA7-APEH-proteasome axis supporting mTORC1 and protein synthesis.\",\n      \"evidence\": \"siRNA, sequential knockdown, proteasome activity and UPR assays with xenograft\",\n      \"pmids\": [\"33753553\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DUB substrate within the axis not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided the crystal structure of UCHL1 with a stereoselective inhibitor, defining a hybrid conformational state and validating monoubiquitin readout of activity.\",\n      \"evidence\": \"X-ray crystallography, activity-based probes and cellular monoubiquitin measurement\",\n      \"pmids\": [\"36216817\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate-bound full catalytic cycle structure not captured\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified HIF-1\\u03b1 stabilization by UCHL1 as cardioprotective after myocardial infarction.\",\n      \"evidence\": \"BioID-MS, CRISPR knockout hiPSC cardiomyocytes and AAV9 delivery in MI model\",\n      \"pmids\": [\"35339825\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct vs indirect HIF-1\\u03b1 regulation not fully separated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined dual osteoclast-regulatory mechanisms: TAZ stabilization at K46 to inhibit NFATC1, suppressing osteoclastogenesis.\",\n      \"evidence\": \"Osteoclast-specific knockout, K46 mutagenesis, reconstituted deubiquitination and NFATC1 transport assays\",\n      \"pmids\": [\"37215988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay with other osteoclast substrates unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified POM121 as a UCHL1 substrate controlling E2F1/c-MYC nuclear transport in neuroendocrine cancers.\",\n      \"evidence\": \"Co-IP, deubiquitination and nuclear fractionation assays with in vivo models\",\n      \"pmids\": [\"38244540\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Selectivity for POM121 among nucleoporins unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked UCHL1 to mitochondrial iron homeostasis and inflammasome control via FDXR stabilization during HCMV infection.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, knockdown and MCMV-infected mice\",\n      \"pmids\": [\"38081437\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"How infection lowers UCHL1 not detailed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established UCHL1 as a driver of pulmonary arterial hypertension through AKT1 stabilization via ubiquitin chain editing.\",\n      \"evidence\": \"Knockout rats, conditional mouse KO, siRNA, inhibitor and K63/K48 ubiquitination assays across three PAH models\",\n      \"pmids\": [\"38695173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of chain-type switching unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined UCHL1 interaction with the NLRP3 NACHT domain and its requirement for inflammasome assembly in microglia.\",\n      \"evidence\": \"Proximity labeling, Co-IP, puncta/ASC oligomerization imaging and chemical inhibition\",\n      \"pmids\": [\"38669140\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NLRP3 is a catalytic substrate not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed UCHL1 stabilizes CD13 in osteoclast precursors to generate an autocrine MAPK-inhibitory signal that suppresses osteoclastogenesis in osteoarthritis.\",\n      \"evidence\": \"Conditional KO and AAV9 overexpression, CD13 ubiquitination assay and MAPK analysis in two species\",\n      \"pmids\": [\"39389988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship to TAZ/NFATC1 osteoclast pathway not integrated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated UCHL1 stabilization of Sox17 supports endothelial angiogenesis and barrier recovery after spinal cord injury.\",\n      \"evidence\": \"IP-MS, Co-IP, conditional KO mice and endothelial functional assays\",\n      \"pmids\": [\"38478109\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Ubiquitination site on Sox17 not mapped\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed a UCHL1/PFKFB3 glycolytic feedback loop sustained by histone lactylation that protects neurons from ferroptosis after spinal cord injury.\",\n      \"evidence\": \"Genetic deletion, K48 ubiquitination and histone lactylation assays with scRNA-seq and SCI model\",\n      \"pmids\": [\"40016338\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Generality of lactylation feedback beyond astrocytes untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How UCHL1 achieves substrate selectivity across its many reported targets and is directed to opposing pro- versus anti-inflammatory and pro- versus anti-survival outcomes in different cell types remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model for substrate recruitment\", \"Context-dependent functional switching mechanism unknown\", \"Most substrate interactions documented in single labs\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [39, 5, 6, 7, 13, 27, 30]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [39, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [34, 36]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 31, 34]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [17, 32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [39, 6, 2, 4, 36]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 8, 30, 38, 2]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [19, 22, 33]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 11]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [13, 25, 18]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [23, 35, 7]}\n    ],\n    \"complexes\": [\"eIF4F\", \"mTORC1\", \"mTORC2\", \"NLRP3 inflammasome\"],\n    \"partners\": [\"TrkB\", \"EGFR\", \"AKT1\", \"HIF1A\", \"PKM\", \"NLRP3\", \"RIPK1\", \"RIPK3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}